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Abstract 
Today, drugs used in treating disease are almost all hydrophobic, which makes them 
unattractive for applying to patients. To overcome this problem, an amphiphilic 
macromolecule was designed which can deliver drugs to the specific targeted area. 
Therefore, this study focuses on the synthesis of water soluble hyperbranched polymers 
and their application in drug delivery systems.  
The first part of the thesis describes the synthesis of water soluble hyperbranched 
polymers by the anionic-polymerisation technique, with p-nitrophenol as the core and 
glycidol as the monomer. The core is important to control the molecular weight of the 
hyperbranched polymer. We then produced five different molecular weights by varying 
the core to monomer ratio, which produced hyperbranched polymers with molecular 
weights of 4000 Da, 8000 Da, 12500 Da, 27000 Da and 50000 Da, and four different 
concentrations of each molecular weight, 1.00 x 10
-4
 M, 2.00 x 10
-4
 M, 4.00 x 10
-4
 M 
and 6.00 x 10
-4
 M. To investigate the performance of the hyperbranched polymers, four 
different hydrophobic molecules were studied. The molecules were naphthalene, 
ibuprofen, tetracarboxyphenyl porphyrin (TCPP) and anti-prion drug. Encapsulation 
studies showed the concentration of each molecule increased with an increase in 
molecular weight and concentration of the hyperbranched polymer 
The functionalisation of folic acid on the surface of the hyperbranched polymer would 
enhance the effectiveness of the polymer as a drug delivery agent for targeting in cancer 
treatment. The above macromolecule was synthesised by conjugation with folic acid 
through poly (ethylene glycol) as spacer. 
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The final chapter of this work describes the encapsulation of two hydrophobic 
molecules, ibuprofen and tetracarboxyphenyl porphyrin with water soluble PAMAM 
dendrimers. PAMAM dendrimers from G0.5 to G2.5 were synthesised.  
The results showed that more drug solubilised, the concentration of both molecules 
increased with an increase in dendrimer concentration. Then a comparison was made 
between encapsulation with water soluble hyperbranched polymers and water soluble 
PAMAM dendrimers. Similar molecular weight was used for both polymers of 4000 Da. 
For both polymers, the result demonstrated that the concentration of drug rose at 2.00 x 
10
-4
 M and plateaued at a polymer concentration of 6.00 x 10
-4
 M. It was suggested the 
above trend was due to the aggregation of polymer. 
The above studies make a valuable contribution to the development of good drug 
delivery systems. 
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Chapter 1: Introduction 
 
1.1  Overview 
Polymers are a large class of materials consisting of many small molecules that can be 
linked together to form long chains, thus they are known as macromolecules.
1
 These 
macromolecules can be classified into three types: 1) linear polymers, where the 
molecules form long chains without branches or cross-linked structures, 2) branched 
polymers which consist of branched molecules, covalently attached to the main chain 
and 3) cross-linked polymers, which have monomers of one chain covalently bonded 
with monomers of other chain.
1
  
Over the past few decades, various attempts have been made to design new 
macromolecules, such as dendrimers and hyperbranched polymers. These polymers 
became attractive to the pharmaceutical industry due to their various applications in drug 
delivery systems. The above polymer is very useful  because it can be synthesised in 
different molecular weight, polydispersity, charge and hydrophilic-hydrophobic 
character of the polymer which can influence drug biodistribution, clearance, biological 
acitivity and toxicity.
2 
 
1.2  Dendritic polymers 
Dendritic polymers which refers to dendrimers and hyperbranched polymers, are highly 
branched macromolecules with a three dimensional dendritic architecture.
3-4
 Dendrimers 
are the stepwise organic synthesis approach to branch-on-branch structures. Ideally, 
dendrimers are spherical, defect-free and perfectly monodisperse compounds. 
Dendrimer synthesis, however, is usually based on tedious multistep protocols. 
Dendrimers are built from a starting atom, such as nitrogen, to which carbon and other 
elements are added by a repeating series of chemical reactions that produce a spherical 
branching structure. As the process repeats, successive layers are added, and the sphere 
can be expanded to the required size. Dendrimers consists of three components: the core 
18 
 
or focal point, interior layers/repetitive branch units or generations (G) which formed the 
dendritic units and terminal functionality at the exterior of the architecture (Figure 1.1).
5
 
 
 
Figure 1.1: The architecture of dendrimer
5 
A second class of branched polymers is the hyperbranched polymers. In contrast to 
dendrimers, hyperbranched polymers are neither defect-free nor perfectly 
monodispersed. These polymers consist of the core, fully reacted (dendritic) and 
completely unreacted (linear) units and terminal units (Figure 1.2). Hyperbranched 
polymers, however, are typically obtained in a one-pot reaction and as a result can be 
easily prepared in large quantities.
6-11
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Core
Terminal
Unit
Linear Unit
Dendritic Unit
 
Figure 1.2: Structure of hyperbranched polymers
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1.3. Synthesis of  dendritic polymers 
1.3.1 Synthesis of dendrimers 
Dendrimers are a relatively new class of macromolecules that have a three dimensional 
structure with a series of layered branches regularly extending from a central core. 
Dendrimers usually consist of three main components :  a multifunctional core, branch 
units and surface functional groups. Two methods that have been developed to 
synthesise dendrimers: the divergent approaches initiated by Vögtle
12
 and further 
applied by  Newkome
13
 and Tomalia
14
 and the convergent method introduced by 
Hawker and Frachet
15
 and also by Miller and Neenan.
16
 
 
1.3.1.1 Divergent approach 
The divergent method (Figure 1.3) involves a stepwise layer by layer approach, which 
the dendrimer grows from a polyfunction core and builds up the molecule towards the 
periphery by the stepwise addition of successive layers of building blocks. Each of these 
layers is called a ‘generation’. The first generation of a dendrimer is formed by attaching 
the branched unit to a focal core. For the second and subsequent generations, the surface 
20 
 
functional group must react with the successive layers of building blocks. This reaction 
is repeated until the desired number of generations is obtained.
17
 
G1 G2 G3
 
Figure 1.3: Schematic of divergent synthesis 
 
1.3.1.2 Convergent approach 
The second method, shown in Figure 1.4 an alternative method of synthesising 
dendrimers. This alternative method is used to produce a more controllable dendritic 
architecture. The formation of the dendrimer begins at the surface functionalities of a 
dendrimer molecule and proceeds inwards by a step addition of branching monomers, 
followed by the final attachment of each branched dendritic subunit to the core.
18-19
 
 
 
Figure 1.4: Schematic of convergent synthesis 
 
      1.3.2 Synthesis of hyperbranched polymers 
Hyperbranched polymers, gained great attention after Florys in 1952 highlighted the 
polymerisation of ABn monomers (where n ≥ 2) to generate highly branched soluble 
polymers. Hyperbranched polymers with similar properties can be easily synthesised 
21 
 
via one-step reactions and therefore represent economically promising products for 
large-scale industrial applications. Unlike dendrimers, these hyperbranched polymers 
are polydisperse systems both in terms of their molecular weight characteristics and 
their branching factors.
20-21
 The general synthesis of hyperbranched polymers can be 
divided into three specific categories: (i) step-growth polycondensation of ABn and 
A2 + B3 monomers, (ii) self-condensing vinyl polymerisation of AB* monomers and 
(iii) multi branching ring-opening polymerisation of latent ABn monomers.
22 
 
1.3.2.1 Step-growth polycondensation 
Step-growth polycondensation of ABn (where n ≥ 2) is extensively used to synthesise 
hyperbranched polymers (Figure 1.5). The branching unit of these  hyperbranched 
polymers is produced when each function of B from one molecule reacts with a 
function of A from another molecule. AB2 type monomers are used because of their 
ease of preparation. A vast range of hyperbranched polymers are produced using 
these techniques, including polyphenylenes, polyesters, polyethers and 
polyamides.
20,23
 Other types of monomers such as AB3, AB4 and AB6 are also used 
to synthesise polyesters and polysiloxanes.  
A
B
B
self condensation ba
B
A
B
B
HBP
 
Figure 1.5: Step-growth polycondensation 
 
     1.3.2.2 Self-condensing vinyl polymerisation 
The second technique uses self-condensing vinyl polymerisation  and was introduced 
by Frechet in 1995 which involves the use of one vinyl group and one initiating 
moiety (AB* monomers) to produce hyperbranched polymers (Figure 1.6). The 
activated species can be radical, a cation or a carbanion. In this process, it is 
preferable to use living or controlled polymerisation (SCVP) to avoid cross-linking 
reactions and gelation caused by dimerisation or chain transfer reactions. 
22 
 
Hyperbranched polystyrenes and poly (methacrylates) have been successfully 
synthesised by using this method.
20
 
 
H2C CH
B
H2C CH
B*
H2C CH
B*
activation propagation
H2C CH
B CH2 CH
B*
*
 
Figure 1.6: Self-condensing vinyl polymerisation 
 
     1.3.2.3 Ring-opening polymerisation 
The last strategy used to produce hyperbranched polymers is the ring-opening 
polymerisation technique which was introduced by Suzuki in 1992 (Figure 1.7). The 
terminal function of a polymer acts as a reactive centre, where further cyclic 
monomers join to form a larger polymer chain through ionic propagation. Each 
additional monomer step produces another reactive centre. This method is used to 
produce hyperbranched polymers such as polyamines, polyethers and  polyesters.
23-25
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Figure 1.7: Ring-opening polymerisation 
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Chapter 2.0: Aims and Objectives 
One of the major problems faced by the pharmaceutical industry is delivering 
hydrophobic drugs to a specific targetted area at a sufficient and safe dosage. Most lead 
drugs are either abandoned or delivered in large quantities to the cell. The uncontrolled 
behaviour of these drugs is due to the poor solubility of the compounds, which can result 
in harmful side effects. Many approaches have been envisaged, including using 
polymeric carriers, such as copolymers and dendritic polymers. Various types of 
polymer have been designed to meet the characteristics required of as drug delivery 
agents, including linear and block copolymers. Another class of macromolecules that has 
gained much attention from researchers are dendrimers. These promising candidates as 
drug carrier were introduced by Newkome
13
 and Frechet.
15
  
Dendrimers are well defined controlled structures, they are monodispersed and highly 
branched macromolecules with a static globular construct. They offer good  key 
characteristic of a delivery agent, such as having a multifunctional terminal surface 
which can modify the surface chemistry,  they are water soluble and  have the ability to 
bind drugs inside their hydrophobic cavity.
12
  Figure 2.1 showed a cartoon of dendrimer 
as delivery agent, especially for cancer treatment. The drug is either encapsulated inside 
the cavity of the dendrimer and/or simply conjugated with the functional groups on the 
surface of the dendrimer. However, synthesising  dendrimers is difficult, time 
consuming and expensive. 
 
  
 
 
Figure 2.1: A Cartoon of dendrimer as a delivery agent 
drug encapsulated inside 
hydrophobic cavity of 
dendrimer 
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Another class of macromolecules, called hyperbranched polymers, can be used as drug 
delivery agents.
4
 Hyperbranched polymers are tree-like structure with a core, a 
branching unit and a terminal group at the surface. Hyperbranched polymers can be 
synthesized using existing polymerization methods and present a more cost-effective 
route for preparing highly branched macromolecules. These polymers are easily 
prepared using one-step synthesis. The ease of preparation, cost effectiveness and scale 
up productions makes them attractive alternatives to dendrimers for many applications.  
In order to overcome the poor solubility of drugs, we proposed water soluble 
hyperbranched polymers as the drug delivery agent. These carriers should be water 
soluble in order to transport drugs in the blood stream to the specific site and be non 
toxic to the human body. A hyperbranched polymer was designed which consists of  a p-
nitrophenol core, a hydrophobic interior and a hydroxyl group as the surface, prepared 
by an anionic polymerisation technique with glycidol as the monomer. An OH group at 
the periphery is important to make the polymers soluble in water. The drug is 
encapsulated in the hydrophobic environment inside the hyperbranched polymer, thus 
the drug is safely trapped inside the polymer, while the outside of the polymer is soluble 
in water.  
For dendrimers, the size increases with an increase in generation, while for 
hyperbranched polymers, the size is increased by varying the core to monomer ratio. In 
this work, we used different core to monomer ratios to increase the molecular weight of 
the polymers. Five different ratios, i.e. 1:5, 1:10, 1:25, 1:50 and 1:100, and four different 
concentrations of each polymer molecular weight,  i.e 1.00 x 10
-4
 M, 2.00 x 10
-4
 M, 4.00 
x 10
-4
 M and 6.00 x 10
-4
 M were explored. An investigation of the encapsulation ability 
of both different sizes and concentrations of hyperbranched polymers were carried out. 
These water soluble hyperbranched polymer were explored as a solubilisation enhancer 
for selected hydrophobic molecules. The molecules used were naphthalene, 
tetracarboxyphenyl porphyrin, ibuprofen and an anti-prion drug. It was anticipated that 
the percent loading, which is theconcentration of the model drug and drug used in the 
25 
 
encapsulation studies would increased as the concentrations and molecular weights of 
the hyperbranched polymer increased.  
It was postulated that the model drugs and drugs were encapsulated inside the polymers 
through a hydrophobic effect between the hydrophobic environment and the 
hydrophobes. The passive release mechanism of the hydrophobes was through diffusion 
from the carriers. 
The modification of hyperbranched polymers with other entities is a promising approach 
to the development of highly efficient drug carriers. The functionalisation of 
poly(ethylene) glycol (PEG) as spacer allows folate to reach and bind to specific 
receptors of cancer cells. Without PEG spacer, the folate will be to crowded at the 
surface of hyperbranched polymers. Figure 2.2 shows a cartoon of these two valuable 
compounds in enhancing polymers as drug delivery vehicles. 
 
 
 
 
 
Figure 2.2 : Cartoon of surface modification of hyperbranched polymers with PEG and FA 
The final part of the thesis presents a comparison of the encapsulation abilities of  water 
soluble hyperbranched polymers and polyamidoamine (PAMAM) dendrimers. The same 
hyperbranched polymers were used as in the previous study. For PAMAM dendrimers, 
we used generation 2.5 with an amine terminated group. These amine terminated group 
were substituted with a hydroxyl group to make water soluble dendrimers. Generation 
2.5 PAMAM dendrimers was chosen because their molecular weight was slightly 
similar to that of hyperbranched polymers with molecular weight at 4000 Da. These 
HBP 
PEG 
FA 
cancerous
cell 
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water soluble dendrimers were encapsulated using ibuprofen and tetracarboxyphenyl 
porphyrin (TCPP). Four different concentrations were used  i.e. 1.00 x 10
-4
 M, 2.00 x 10
-
4
 M, 4.00 x 10
-4
 M and 6.00 x 10
-4
 M. On comparing the results  it was postulated that  
both hyperbranched polymers and dendrimers showed same trend where the 
concentration increased until it plateaued at the highest concentration. 
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Chapter 3: Polymers and Drug Delivery Systems 
3.1 Overview 
The development of polymers with new chain architectures and structures has become in 
the past decade an intense research field in close interaction with the rapid growth of 
nanoscale technologies. Much effort in this area has focused on the controlled synthesis 
and the use of highly branched polymer architectures since new and specific properties 
can arise directly from the size, shape, and capacity of such nanometric-sized 
macromolecules.
26
 Due to these properties, polymer chemists are actively involved in 
designing polymer materials for biomedical application. One field of application that has 
had the attention of chemists since the late 1960s is the need for advanced drug delivery 
systems to improve drug efficacy.
27
 
 
During the past few decades, a large number of drug delivery systems, mostly in the 
forms of microspheres, films, tablets, or implantation devices, have been designed to 
achieve sustained drug release by taking advantage of the peculiarities of polymers.
2
 
Today, the concept of drug delivery is not limited to prolonging the duration of drug 
release; instead, it applies to at least two strategies of realizing temporal and spatial 
distribution control in the body. Temporal control stresses the selection of predetermined 
kinetics of drug release during treatment, whereas spatial distribution control aims to 
precisely direct a drug vehicle to the desired sites of activity.
28-29
 For such controls, 
significant efforts have been devoted to explore nanotechnology based on the 
intersection of multiple disciplines of chemistry, biology, and engineering.  
 
Nanotechnology focuses not only on formulating therapeutic agents in biocompatible 
nanocomposites but also on exploiting the distinct advantages associated with a reduced 
dimensional scale within 1-100 nm. Some examples of nanoscaled polymeric carriers 
involve polymer conjugates, polymeric micelles and polymersomes.
30
 Because these 
systems often exhibit similarity in their size and structure to natural carriers such as 
viruses and serum lipoproteins, they offer multifaceted specific properties in drug 
28 
 
delivery applications. These system can be used to delivering drugs to targeted area 
(cellular/tissue).
30
 
 
3.2 Polymer architecture and drug delivery 
As various nanosystems have been developed, the importance of polymer architecture-
property relationships has gradually been realized and emphasized. Polymer architecture 
describes the shape of a single polymer molecule, which often determines its 
physiochemical properties
2
 Any polymer selected for drug delivery formulation is 
commonly classified according to it’s chemical nature such as polyester, polyanhydride, 
poly (amino acid), backbone stability (biodegradable, nonbiodegradable), and water 
solubility (hydrophobic, hydrophilic).
27
 Polymer architectures that are relevant to drug 
delivery applications are presented in Figure 3.1. 
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       Homopolymer                  AB type diblock copolymer                  ABA type triblock copolymer 
      Random copolymer                                                                         BAB type triblock copolymer 
Alternating copolymer                                                                   ABC type triblock copolymer 
A. Linear Polymers 
 
B. Branched Polymers 
star shape polymer                star shaped block copolymer 
hyperbranched polymer 
graft copolymer 
block dendrimer                             dendri-graft copolymer 
dendrimer 
C. Crosslinked polymers 
Figure 3.1: Polymer architectures : A.  Linear polymers, B. Hyperbranched polymers and  
C. Crosslinked polymers
2
 
Polymer networks           interpenetrating polymer networks (IPN)                semi IPN 
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Linear polymers  such as polyethylene glycol (PEG) which consist of homopolymers or 
copolymers, have the simplest main architecture was and were first reviewed for drug 
delivery in the early 1950s.
2
 At this time, chemists had started to link drugs onto 
polymers to improve their efficiency. However, during that time, they concentrated 
mainly on the chemistry itself and almost any class of polymers was covalently 
combined with any class of drugs. The biological aspects of the design of polymeric 
prodrugs were hardly taken into account. In 1975, Ringsdorf proposed a model based on 
the combined chemistry and biology approach  consisting of five main elements: 
polymeric backbone, drug, spacer, targeting group, and solubilizing moiety (Figure 
3.2).
2,31
 This model is used by  polymer chemists to design tailor-made polymeric 
carriers that can fulfil the specified requirements of drug delivery systems. 
 
 
 
 
 
 
Figure 3.2: Ringsdorf’s model of a polymer-drug conjugate 
 
3.2.1 Linear polymer for drug delivery 
Over the past 20 years, water soluble linear polymers have been developed for potential 
drug delivery. These includes vinyl polymers, polysaccharides, poly(amino acids), 
proteins and poly(ethylene glycol) (PEG). One example of vinyl copolymers which was 
succesfully synthesized using radical polymerisation is N-(2-hydroxypropyl 
methacrylamide) or HPMA. This polymer has been conjugated with the anti cancer 
agent doxorubin and entered phase I clinical trials as PK1 (FCE286068, Figure 3.3 ) in 
1994.
2
 Later, PK1 also reached phase II clinical trials for the treatment of breast and 
colon cancers.  
spacer 
drug 
Solubilizing 
moiety 
Targeting  
group 
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Figure 3.3: Poly(N-(2 hydroxypropyl methacrylamide)) copolymer containing 
doxorubin PK1 (FCE28068) 
 
Biodistribution, immunogenicity and biological activities have proven that poly HPMA 
is non toxic and non immunogenic in vivo.
32
 The characteristics that should be taken into 
consideration in the development of a polymer as a drug carrier include molecular 
weight, polydispersity, charge and the hydrophilic-hydrophobic character of the polymer 
backbone. The latter because it can adversely effect drug biodistribution, clearance, 
biological activity and toxicity to the cell. A higher molecular weight of the polymer 
carriers was achieved by binding a drug to the polymer. As a result, this polymer drug 
conjugate can significanlty change the biodistribution of the conjugates and also 
enhances the circulation times and results in better accumulation at the targeted site.
33
 
 
Drug conjugated linear polymer was first introduced to deliver drugs. The disadvantages 
of this architecture was increased in molecular weight will significantly increased the 
biodistribution of drugs because molecular weight can affect the effectiveness of the 
carrier. Another factor was solubility, the solubility of drug will improved when 
conjugated with water soluble linear polymer. However, the solubility of the polymer 
itself would decreased. Another class of polymer, named block copolymer can be used 
as delivery agent in drug delivery system and are discussed in the next section. 
32 
 
3.2.2  Block copolymer and drug delivery 
Block copolymers consist of polymers that have two or more blocks in the main chain 
and can be categorized by their architectures as AB type block copolymers, ABA 
triblock and multiblock copolymers (Figure 3.1). The A unit represents the soluble 
block in the selected solvent and the B unit is the insoluble block. Linear amphiphilic 
block polymers, which consists of both hydrophilic and hydrophobic blocks in the same 
polymer chain, can build spherical polymeric assemblies in aqueous solution called 
polymeric micelles. These polymeric micelles can act as a drug carrier where the drug is 
conjugated to one segment of the block polymer to form the core and the other segment 
was PEG, which remains unmodified as a water soluble shell.
21,31
  Block copolymer 
have been succesfully used in drug delivery to target drug to specific physiocological 
sites such as organs, tissues or cells, to solubilise hydrophobic drugs, to increase drug 
stability and to control drug release.  
 
There are three major types of micelles that contibute to drug delivery systems based on 
linear block copolymers: (a) common block copolymer micelles; (b) drug-conjugated 
block copolymer micelles; (c) block ionomer complex micelle (Figure 3.4).
2
 
 
 
Figure 3.4: Three major types of micelle : (a) common block copolymer 
    micelle, (b) drug-conjugated block copolymer micelle and  
(c) block ionomer complex micelle 
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Polyethylene glycol (PEG) is also an excellent biocompatible biomaterial due to its 
flexibility, non-toxicity and hydrophilicity. An example of this group is  
methoxypolyethylene glycol-b-poly(D,L,-lactide) (PDDLA) (MePEG:PDDLA). This 
block copolymer was developed for micellar carriers of hydrophobic drugs such as 
paclitaxel.
34 
This drug has been successfully incorporated into a micellar solution with 
up to 5% w/v of paclitaxel. Paclitaxel is an anti cancer drug that is used in 
chemotheraphy for the treatment of lung, ovarian, breast, head and neck cancer.
35-37
                
 
Drug conjugated block copolymer micelles are developed by taking advantage of the 
interaction between a drug and a hydrophilic block copolymer segment to build the 
hydrophobic polymer-drug core of micelles. An example of this type is the anti cancer 
polymer conjugated drug onto biodegradable block copolymers of PEG with Doxorubin 
attached via an enzymatically degradable glycine-phenylalanine-leucine-glycine (Gly-
Phe-Leu-Gly) spacer (Figure 3.5).
2,36
  
 
 
Figure 3.5: Block copolymer of PEG conjugated with Doxorubin drug via 
enzymatically degradable Gly-Phe-Leu-Gly spacer 
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This conventional micelle drug delivery has some disadvantages which were easily 
disassemble once the concentration falls below the critical micelle concentration. To 
overcome these classical micelles, we suggested static unimolecular based on dendritic 
or hyperbranched polymer to deliver drugs efficiently. These static unimolecular has a 
static structure, controlled shaped and molecular weight and furthermore has well 
defined surface fucntionalities.
37
 
 
3.2.3. Dendritic polymers for drug delivery  
Polymer based drug delivery systems are designed to improve the pharmacokinetics and 
biodistribution of a drug and/or provide controlled release kinetics to the specific target. 
Ideal dendritic polymers should exhibit high aqueous solubility and drug loading 
capacity, biodegradability and low toxicity. In dendritic polymers drug delivery, a drug 
is either encapsulated in the interior of the polymer and/or it can be conjugated at the 
surface terminal to form macromolecular prodrugs. 
 
 
3.2.3.1 Drug encapsulated dendritic polymer 
Poly(glycerol succinic acid) dendrimers (PGLSA dendrimers) were investigated as a 
container for camptothecin, a group of naturally derived hydrophobic compounds with 
anti cancer activity. The anti cancer activity was investigated for human cancer cells 
such as HT 29 colon cancer, MCF-7 breast carcinoma, NCI-H460 large lung carcinoma 
and SF-268 astrocytoma.
38
 
 
To improve the solubility of the dendrimers, carboxylate (G4-PGLSA-COONa) at the 
pheripheral groups were used and succcesfully  encapsulated with 10 
hydroxycamptotecin (10 HCPT) (Figure 3.6). Upon exposure to MCF-7 human breast 
cancer cells, the unloaded dendrimer showed no cytotoxicity while 10 HCPT 
encapsulated with G4-PGLSA-COONa showed significant toxicity with less than 5% of 
viable cells at higher concentrations (20 µM).
38
 
35 
 
 
 
Figure 3.6: Encapsulated G4-PGLSA-COONa dendrimers with 10 
Hydroxycamptothecin
38
 
 
3.2.3.2 Drug conjugated dendritic polymer  
Dendritic drug conjugates or prodrugs consist of a drug that is chemically bound to the 
peripheral groups of macromolecules. There are three pathways
39
 to create these 
prodrugs; i) direct conjugation of the drugs to the dendritic surface, ii) conjugation via a 
linker molecule and iii) drug molecules can become an integral part of the dendritic 
carrier and released through certain triggering events at the desired location. PAMAM-
G2.5-COOH (Figure 3.7) and PAMAM-G3-NH2 has been conjugated with the 
methotrexate drug.
39
 
36 
 
 
Figure 3.7: PAMAM-G2.5-COOH conjugated with methotrexate drug 
 
3.3  Structure and properties relationship 
3.3.1  Biocompatibility 
A major concern when introducing a polymers into medical applications is its 
biocompatibility. These polymers should exhibit low toxicity and non immunogenicity 
to the cells. The biocompatibility of a polymer is dependent on the identity of the 
functional groups that are sufficiently exposed to interact with the biological tissues.
36,40-
41 
 Encapsulation of enzymatically unstable or non compatible functionalities to a highly 
branched polymer architectures can reduce he access to the core of a macromolecule and 
further minimize the undesired interactions in vivo. This is due to the highly branched 
polymers which can modulate the biocompatibility of polymer. For instance, polymer 
backbone such poly (ethylene glycol) (PEG), poly N-(2-hydroxypropyl methacrylamide) 
(PHPMA) and styrene-co-maleic anhydride (SMA) are biocompatible and have been 
extensively used in clinical studies.
40
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In order to improve the water solubility and biocompatibility of polymers, PEGylation 
technique was introduced. This technique is widely used to improve the biological utility 
of small molecules, proteins, polymers, surfaces and artificial organ implants.
40
 PEG 
grafts have been used to increase the water solubility and reduced the cytotoxicity of 
several linear polymers such as polycaprolactone (PCL) and poly-(N-
isopropylacrylamide-co-maleic anhydride). For copolymers, which have the similar 
weight ratios of branched polyethyleneimine (PEI) and PEG, a shorter chain of PEG is 
better than a single larger PEG distributed throughout the structure to improve the 
biocompatibility of the polymer (Figure 3.8). This is due to shorter PEG chains reduced 
cytotoxicity effectively than fewer longer PEG. Other factors that should be considered 
to minimize the cytotoxicity of these copolymers include reducing the number of 
primary amines or the larger weight percentage of linkers. 
 
Figure 3.8: Conjugation of PEG to PEI: (a) a few longer PEG chain and 
(b) numerous shorter PEG chain 
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The surface of the copolymers should also have high solubility in an aqueous medium. 
For amino-terminated poly(amidoamine) (PAMAM), a cationic surface destabilizes the 
cell membrane and instigates cell lysis. Furthermore, the cytotoxicity of the amino 
terminated dendrimer is generation dependant with higher generation dendrimers being 
the most toxic.
36
 Other factors that contribute to the toxicity of amino-terminated 
dendrimers include the type of amine functionalities being used as primary amines are 
more toxic than secondary amines. However, the cytotoxicity of a cationic dendrimer 
can be improved by conjugation with comparable end groups such as PEG (Figure 
3.9).
40-41
 
 
Figure 3.9: G4 PAMAM dendrimer with PEG as the end group functionalisation
40
 
Anionic surface functionalities show lower cytotoxicity compared to cationic 
dendrimers. Lower generation PAMAM dendrimers possessing carboxylate surface 
group are neither haemotoxic or cytotoxic at wide range of concentrations.
8
 Dendrimers 
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containing an aromatic polyether core and anionic carboxylated surface groups show 
significant haemolytic activity in rat blood cells after 24 hours. The aromatic interior of 
the dendrimer may cause haemolysis through hydrophobic membrane contact. However, 
the influence of the dendrimer core diminishes  with increasing dendrimer generation 
and rigidity of the dendritic branches that form the shell around the core. The rigidity of 
the shells encapsulates the core unit and prevents interaction between the core and the 
surface segments.
42-44 
 
 
3.3.2 Biodegradability 
Biodegradability is an important factor for a macromolecule being used in biomedical 
applications.
40
 Higher molecular weight polymers show promising properties as a 
delivery component but larger molecule ( more than 40 kDa) can accumulate in the body 
and caused undesired side effects. The incorporation of biodegradable linkages is vital 
for the cleavage and clearance of the polymeric carriers. Natural polymers such as 
polysaccharides and polypeptides are suitable candidates for biodegradable materials. 
Polysaccharides such as cellulose, dextran,  hyaluronic acid, chitin and chitosan are 
employed for drug delivery due to their characteristics such as ease of functionalisation, 
efficient enzymatic degradation and relatively low immunogenicity.
40 
 
Synthetic polyester such as poly(glycolic acid), poly(lactic) acid and poly(caprolactone) 
are stable for short periods yet degradable over long periods into small molecules 
components  via enzymatic or hydrolytic cleavage. Other synthetic polymers that have 
been investigated for biodegradable materials including poly(amides) and 
poly(orthoesters).
40
 
 
 
 
40 
 
3.3.3  Biodistribution 
The synthetic polymer drug carrier designed for drug delivery depends solely on its size 
and surface functionalities. Ideally, the carrier must have minimal non-specific 
interactions and accumulate at the desired receptor. However, the polymer drug carrier 
will also interact with sites throughout the body. Therefore, it is important to design a 
drug carrier that has a optimum capability of accumulating at the desired site and 
causing  minimum toxicity to other cells.
45
 The critical factor in controlling 
biodistribution is to increase the blood circulation time. Increased blood circulation 
means that the macromolecule drug conjugate is in the bloodstream and can interact with 
the desired targeted site. A higher molecular weight can prolong the circulation time, but 
it can also interact with other healthy organs.
40
 
The preferential delivery of drugs to the specific site is the crucial factor for an effective 
macromolecular therapeutic. The polymer carrier should be designed to enable sufficient 
exposure to the specific targeting site while minimising accumulations in other parts of 
the body.
40,45
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3.4 Results and discussion 
3.4.1  Water soluble hyperbranched polymers  
At present, people are often faced with the pressures of life, which causes them to take 
medication to relieve pain. Among the most common drugs taken is ibuprofen. The main 
problem of ibuprofen or other hydrophobic drugs is that they have poor solubility, and 
are not easily absorbed into the bloodstream. Consequently, most lead drugs are either 
abandoned or delivered in large quantities to the cell. Many approaches have been 
envisaged including using polymeric carriers, such as copolymers, polymer aggregates 
and dendritic polymers. One promising delivery agent is the dendritic polymer 
(dendrimers and hyperbranched polymers).   
 
Dendrimers, are highly branched macromolecules, that are monodisperse, possess a 
globular shape and have large numbers of controllable surface functionalities. Even 
though this carrier has perfect characteristics, they are not easy to synthesise. Their  
synthesis is time consuming, which makes it very expensive. Another issue raised is 
their toxicity to the human body. For example, amine-terminated polyamidoamine 
(PAMAM) dendrimers, have significant toxicity to human intestinal adenocarcinoma 
cells. Another concern is cytotoxicity, which is found to be generation dependant, with 
higher generation dendrimers being most toxic to the human body.
36
 
 
In contrast, hyperbranched polymers are spherical, branched macromolecules possessing 
a specific architecture, the key scheme of which includes the core, the interior branching 
units and the terminal end groups. This polymers are easy to synthesise using a one step 
reaction. These polymers are currently attracting much attention from the 
pharmaceutical industry as dendritic carriers in drug solubilisation and delivery 
applications. To produce a hyperbranched polymer suitable for the applications 
described above, a polymer is needed that is non-toxic to humans and readily dissolves 
42 
 
in water. So, a hyperbranched polymer with a hydroxyl terminal group was prepared, as 
a solubilisation enhancer for hydrophobic drugs. 
Initially,  p-nitrophenol  was chosen as a core because it consists of an aromatic structure 
and an OH group. Aromatic structure is important because it can be easily detected by 
NMR. The molecular weight of hyperbranched polymers can be calculated using this 
aromatic signal in NMR. The calculation will be described later in this chapter. The OH 
group is easily deprotonated by a base to form a phenoxide before further propagation 
with the monomer (glycidol). This commercially available monomer is a reactive 
hydroxy epoxide which represents a latent AB2 monomer (wherein the B groups of the 
monomer are only activated for polymerisation after the preceding reaction of the A 
group)
46-48 
 that can be further polymerised to hyperbranched polyethers with numerous 
hydroxyl terminal groups. These macromolecules possess a hydrophobic interior and  
hydrophilic OH groups at the periphery.
48 
A representative structure is shown below in 
Figure 3.10. 
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Figure 3.10: Hyperbranched polyglycerol with a p-nitrophenol core 
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In the first part of this work, hyperbranched polymers of controlled molecular weight 
were synthesised. Further investigation was carried out into the ability of these polymers 
to solubilise four different UV active species. These compounds were naphthalene, as a 
model hydrophobic compound and ibuprofen, a commercial non-steroidal anti-
inflammatory drug (NSAID), used widely in the treatment of pain and fever. Another 
compound used was tetracarboxyphenyl porphyrin (TCPP), which is used as  a 
photosensitizer in photodynamic therapy. The final drug was an anti-prion drug, used to 
treat mad cow disease. 
                                      
3.4.2  Synthesis of polyglycerol hyperbranched polymers        
Hyperbranched polymers can be synthesised with or without a core. Hyperbranched 
polymers synthesised without a core will lead to an uncontrolled molecular weight of 
polymer. In this study, p-nitrophenol was chosen as the core to control the molecular 
weight of the polymers. Hyperbranched polymers were synthesised with different core 
to monomer ratios, which led to a several polymer molecular weights. Various polymer 
molecular weights allowed investigation of the effect of molecular weight on the 
encapsulation and release of drugs. 
 
Initially, synthesis was carried out using a p-nitrophenol core and glycidol as the 
monomer, with a core/monomer mixture  (1:5) mole ratio (Scheme 1). All glassware 
was thoroughly cleaned and dried in an oven. The polymer was synthesised using 
diethylene glycol dimethyl ether as the solvent. The synthesis was carried out in a 
nitrogen environment. The reaction started with the addition of the core to solvent in a 
three neck round bottom flask. The mixture was heated to 50 
o
C until the entire core was 
dissolved. The temperature was raised to 90 
o
C prior to the addition of NaH.  Glycidol 
was then added slowly over 12 hours using a syringe pump. Slow monomer addition was 
crucial to minimise secondary polymerisation that can occur without the initiator or 
core.
47
 The mechanisms are discussed later in this chapter. 
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Scheme 1: Synthesis of hyperbranched polymers 
 
The prepared polymer was dissolved in methanol before being precipitated in acetone to 
remove unreacted monomer or small oligomers. This step was repeated twice and the 
final product was dried overnight in a vacuum oven at 30 
o
C. The product was a brown 
viscous polymer with 40% yield. Confirmation of the polymer structure was done using 
1
H NMR. The spectrum showed aromatic protons characteristic of the p-nitrophenol 
core at 8.16 and 7.05 ppm. This represents Ha and Hb in the core molecule in Figure 
3.11. Ha was the more deshielded due to it’s position near the electron-withdrawing 
group, NO2.   
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O2N OH
HbHa
Ha Hb  
Figure 3.11: p-nitrophenol 
 
To confirm that the core was totally incorporated inside the polymer rather than simply 
mixed, another experiment was carried out. To the synthesised polymer, fresh p-
nitrophenol was added and physically mixed before the 
1
H NMR spectrum was 
reacquired. Figure 3.12 shows the original 
1
H NMR spectra from a previous sample, 
and  Figure 3.13  shows  the freshly doped p-nitrophenol to the sample. Figure 3.12 
shows that there were an additional two doublets at 8.14 and 6.85 ppm respectively, 
which is attributed to the two new peaks of freshly doped p-nitrophenol. This confirmed 
that the core molecule was chemically incorporated into the polymer structure. A broad 
peak in the range of 2.35 to 4.05 ppm was attributed to the remaining protons in multiple 
proton environments within the polymer, which were CH, CH2 and OH groups. 
 
 
 
 
               
 
Figure 3.12: The original 
1
H NMR representing the core of the polymer 
 
Ha 
 
Hb 
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Figure 3.13: The freshly doped p-nitrophenol to the polymer 
 
To prove that the hyperbranched polymers were fully synthesised, further 
characterisation using FTIR was performed. The FTIR result revealed a broad OH peak 
at 3420 cm
-1
, CH2 at 2873 cm
-1
 and a carbonyl peak at 1643 cm
-1
. The molecular weight 
(Mn) from GPC was 4000. A solubility test showed  that these hyperbranched polymers 
were easily dissolved in water. 
 
In this work, several attempts were made to polymerise hyperbranched polymers with 
different molecular weights. This can be achieved by varying the core to monomer ratio. 
For example, the first trial was to polymerise  a hyperbranched polymer using a 1:5 mole 
ratio, and the expected molecular weight was 500 Da. The expected molecular weight 
was calculated by multiplying the molar mass of glycidol (74.08 gmol
-1
) by 5 and adding 
the molar mass of the p-nitrophenol core (139.11 gmol
-1
). The core should be totally 
dissolved in the solvent. Ideally, when polymerisation occurred, it was expected that one 
molecule of the core would be incorporated with one molecule of the  polymer. 
 
From the aqueous GPC result, the calculated molecular weight (Mn) was around 4000 
Da relative to linear PEG-PEO with a polydispersity of 1.85 in an aqueous solution. This 
Freshly doped para-nitrophenol 
Para-nitrophenol incorporated as core 
of the polymer 
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is much higher than the calculated molecular weight. Therefore, it could be argued here 
that the core is doing nothing. However, the polydispersity suggested otherwise. If this 
polymerisation was carried out without a core, the polydispersity could be around 10. 
 
From the 
1
H NMR spectra, when the core peak was integrated relative to the broad peak 
of the polymer backbone, the calculated molecular weight was around 7000 Da. The 
difference between these two values is discussed here. When the core and monomer 
began  polymerisation, some core molecules were incorporated well into the polymer 
molecule and others were not. But GPC cannot differentiate between the polymers with 
or without a core. As a result, it calculated all the polymers as bulk. Another 
contributing factor was the way that the GPC was calibrated. The GPC was calibrated 
against linear polystyrene and underestimated the Mn of the dendritic molecules.
49
 This 
is because the branched structure of the dendritic molecules gave a compact 
configuration compared to linear molecules of the same molecular weight. For these 
reason, GPC provided a minimum value of Mn, (Mn
min
). 
 
In contrast to 
1
H NMR, Mn was calculated by integrating the p-nitrophenol core peak at 
δH = 8.16 ppm with the abundance of proton peaks from the polymer backbone, with δH 
in the range of 2.35 to 4.05 ppm (not shown). From this integration, the calculated Mn 
was 7000 Da. This value was higher than  GPC due to 
1
H NMR calculations based on 
the assumption that each polymer molecule contained  a core molecule. Thus, the Mn 
from the 
1
H NMR calculations will always be high and represents the maximum value, 
(Mn
max
). 
 
Earlier discussion mentioned that the core to monomer ratio used was 1:5. It was 
predicted that the molecular weight is 500 Da. However, results from the GPC and NMR 
were different from the directly calculated molecular weight. The following discussion 
is about the mechanism involved in the synthesis of hyperbranched polymers. The 
mechanism of hyperbranched polymers polymerised using a p-nitrophenol core and 
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glycidol as the monomer is shown below. It involves two steps:  initiation of the core 
and propagation of the monomer. For the first step, the reaction was initiated by 
deprotonation of the core 1 by sodium hydride before the slow addition of glycidol 
monomer was started. The anionic core, called phenoxide 2, was then reacted with 
glycidol 3 by a ring-opening mechanism to form an alkoxide 4 (Scheme 2). The next 
step was the propagation of the monomer to form a new alkoxide 5 before further 
propagation to form hyperbranched polymers (Scheme 3).  
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Scheme 2 : Deprotonation and ring opening mechanism of the monomer 
O
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O
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Scheme 3 : Propagation of alkoxide to form hyperbranched polymers 
 
However, the above route did not always occur. Sodium hydride is a strong base, and if 
any remains after initiation, it can also deprotonate glycidol 3 and form a glycidol 
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initiator 6, which is depicted in Scheme 4 below. When this happens, a non-cored 
polymer is produced.    
O
O
H
H
O
O
O
HO3
6
non-cored hyperbranched polymer 
Scheme 4 : Deprotonation of glycidol to form a glycidol initiator 
 
Another deviation from normal polymerisation can occur if, water 7 is present in the  
reaction.  It can form a hydroxide ion that further reacts with glydicol 3, which leads to 
the formation of anion 8 (Scheme 5). Again, a non-cored polymer is produced. 
H
O
H
H
O
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O
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7 3 8
O
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non-cored hyperbranched polymer
3
 
Scheme 5: The presence of water may affect the final product of polymer 
 
After the first attempts to polymerise hyperbranched polymers with a 1:5 ratio had 
succeeded, it was attempted to polymerise the same hyperbranched polymers with 
different core to monomer ratios. The selected ratios were 1:10, 1: 25, 1:50 and 1:100. 
For this work, precise control of molecular weight was required (for example, a 1:5 ratio 
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actually gave a molecular weight of 500). The investigation was to determine the ratio of 
monomer could affect the molecular weight, i.e. more monomer will increase the 
molecular weight. The spectroscopy results showed that the polymers exhibited the same 
characteristic peaks as before. The GPC results showed that the molecular weight of the 
polymers range from low to medium to high, as shown in Table 3.1. As predicted, the 
estimated molecular weights for all the ratios were different from those calculated by 
GPC and NMR, as described earlier.  
 
Table 3.1: Different molecular weights of polyglycidol  
Polymer 
ratio 
Estimated molecular 
weight* 
Molecular weight 
by GPC 
Molecular weight 
by NMR 
Polydispersity 
1:5 500 4000 7000 1.8 
1:10 900 8500 8500 2.0 
1:25 2000 12500 13000 2.3 
1:50 4000 27500 2130000 3.5 
1:100 7500 50000 ** 6.0 
*based on core to monomer ratio 
**molecular weight could not be determined as of the peak were barely visible and could not be 
accurately integrated relative to the polymer 
 
The table above shows that hyperbranched polymers with different molecular weights 
were successfully synthesised. These different molecular weights were used to 
investigate the performance of the polymers in drug delivery. 
 
3.4.3 Selection of model drug for encapsulation study 
Initially, the study was started using a very simple molecule, which was readily available 
in our lab. After this attempt succeeded, we then used a model drug and drug 
(naphthalene, tetracarboxyphenyl porphyrin and ibuprofen) with some solubility and 
finally, a real drug was used to assess the efficiency of the polymers. 
 
In this work, several compounds were chosen and encapsulated with the synthesised 
hyperbranched polymers. The selected compound should be at least partially soluble in 
aqueous solution and be UV active. Naphthalene was used to start with, as it is readily 
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available in our lab. Naphthalene (9) is a compound that consists of two benzene rings 
fused together and shows some solubility in water. The second compound which was a 
model drug, ibuprofen (10), has a carboxylic functional group and shows some solubility  
in water. These two compounds are available commercially. 
 
The third compound was from the porphyrin group. This group has aromatic 
heterocycles with pyrrole groups. They are a highly conjugated system and have an  
intense peak in the visible region. The type of porphyrin used was tetracarboxyphenyl 
porphyrin (TCPP) (10) which exhibits some solubility in water. Having studied the 
compounds, it was desirable to investigate with a real drug. The final drug used was an 
anti-prion drug  (11) which was synthesised by another group in the department (Figure 
3.14). This drug does not dissolve in water. Table 3.2 represents the physical properties 
of all molecules used for this study. 
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Figure 3.14: Structure of (9) naphthalene and (10) ibuprofen, (11) tetracarboxylphenyl 
porphyrin and (12) anti-prion drug 
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Table 3.2: Physical properties of model drugs and drugs used in the encapsulation studies 
 
 Naphthalene Ibuprofen Tetracarboxyphenyl 
porphyrin 
Antiprion drug 
Molecular weight 
(gmol
-1
) 
128.17 206.28 854.33 312.30 
Empirical formula C10H8 C13H18O2 C48H31N4O8 C17H13FN2O3 
Characteristic 
wavelengths (nm) 
219 222 415 350 
Solubility* 
(x 10
-4
 M) 
         0.58                  2.68                           0.72 Not soluble in 
water 
*The solubility was determined using the same experimental method and condition and 
no effort made to maximise it 
 
 
3.4.4  Encapsulation studies 
Five types of hyperbranched polymers with different molecular weights, as previously 
described were synthesised by varying the core to monomer ratio using the method  
shown in Scheme 1. The five different molecular weights (Mn) synthesised were 4000 
Da, 8500 Da, 12500 Da, 27500 Da and 50000 Da. 
 
In order to select the right concentration ranges to use in this study, a series of 
experiments were performed. For example, if the range was too small, the concentration 
of polymer rose with increased concentration of guest molecule. After several attempts, 
four different concentrations of each polymer, i.e. 1.00 x 10
-4
 M, 2.00 x 10
-4
 M, 4.00 x 
10
-4
 M  and 6.00 x 10
-4
 M were prepared to explore the maximum loading of the model 
drug (TCPP and naphthalene) and other drugs (ibuprofen and anti-prion) used in this 
study.  
 
The selected guest molecules under study were naphthalene, ibuprofen and 
tetracarboxyphenyl porphyrin (TCPP). The studies were carried out in  a buffer solution 
at pH 7.4 and room temperature. The buffer solution used was tris(hydroxymethyl) 
aminomethane (TRIS) with 0.1 M and pH 7.4. The result obtained from these 
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experiments indicated the behaviour and interaction between the polymer and guest 
molecules.  
 
As a control, the complexation experiment was repeated without the hyperbranched 
polymers. The excess model drugs and drug were dissolved in water and filtered. The 
solution was then assessed by UV-Vis spectrophotometer.  The concentration was 
determined by dividing the absorbance with each individual extinction coefficient (ɛ) of 
model drugs and drug. The ɛ value was determined from Beer-Lambert plot. All values 
were higher than we determined because the data were obtained using experiments 
specially designed to maximise solubility (sonication, heating, etc.). In our work, we 
made an effort to collect all datas using the same experimental conditions (without 
heating and at room temperature). It was believed these method is more reasonable as it 
used the same method and equipment to record all datas and make them comparable. 
 
3.4.4.1  General method for complex formation 
As mentioned earlier, water soluble hyperbranched polymers were successfully 
synthesised with different molecular weights ranging from 4000 to 50000 Da. To 
establish the validity of the technique, a hyperbranched polymer with a molecular weight 
of 8500 Da was used. If successful, this would be followed by encapsulation with 
different molecular weights and concentrations. Several methods were used to 
performed the encapsulation. The first attempt was to mix the guest molecule and 
polymer in water. Even though the polymer dissolved easily in water, the guest molecule 
was hard to dissolve. A co-precipitation
46
 method was then used. 
 
The method involved the dissolution of a water soluble hyperbranched polymer and 
model drug/drug separately in methanol. This was to ensure that the crystal lattice of 
both substances was collapsed fully.
46
 The methanol was then removed in vacuo to give 
the hyperbranched polymer/drug co-precipitate. This step was followed by the addition 
of buffer solution at 0.1M and pH 7.4, and the solution was filtered to remove 
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undissolved guest molecules. Drug concentrations for all prepared samples were 
assessed using a UV-Vis spectrophotometer. 
 
3.4.5 Encapsulation of naphthalene with hyperbranched polymers  
The first attempt to investigate the ability of hyperbranched polymers to solubilise a 
hydrophobic molecule was done using naphthalene, which has a UV chromophore at  
λmax = 219 nm in methanol and has low solubility in water at 30.00 mg/L (2.34 x 10
-4
 
M). Naphthalene is a hydrophobic compound and the structure consists of two fused 
benzene rings with a molecular weight of 128.17 g/mol.  
 
For the first attempt, a hyperbranched polymer  (10.00 mg) with a molecular weight of 
8500 Da and 10.00 mg of naphthalene was used. Both  were dissolved in 10 ml 
methanol in two different vials. After both were dissolved, they were physically mixed 
and all solvents was removed using a rotary evaporator. Finally, 10 ml water was added 
and the undissolved solid was filtered. The solution was assessed using a UV-Vis 
spectrophotometer at its characteristic wavelength. When naphthalene was incorporated 
into hyperbranched polymers, the solubility of naphthalene increased from 33.58 to 
45.37 mg/L (Figure 3.15). 
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Figure 3.15: UV-Vis spectra of naphthalene encapsulated with hyperbanched polymers 
 
Further investigation were conducted using different concentrations and different 
molecular weights. For example, to prepare a sample with a concentration of 1.00 x 10
-4 
M, 8.00 mg of hyperbranched polymer with a molecular weight of 4000 was dissolved 
in 10 ml methanol. An excess of naphthalane was also dissolved in 10 ml methanol. 
Both solution were physically mixed. All solvent was removed using a rotary 
evaporator. Buffer solution was added and finally all undissolved solid was filtered. All 
the prepared samples were measured by UV-Vis spectrophotometer.  
 
The absorbance was too strong; therefore, dilution was needed in order to achieve an 
absorbance of less than 1. All samples were diluted 20 fold. The final concentration 
value of all samples was determined by dividing the absorbance by the extinction 
coefficient (ε) of naphthalene and multiplying by the number of dilutions. This 
extinction coefficient value was determined graphically from a Beer-Lambert plot as  
41945 M
-1
cm
-1
. This plot was prepared using naphthalene dissolved in methanol. The 
reason that methanol was used instead of water was that naphthalene does not dissolve 
easily in water, while methanol has the same polarity as water and inside the 
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hyperbranched polymer. This allowed us to make a comparison with any encapsulated 
product. The concentration of naphthalene after encapsulation in a series of 
hyperbranched polymers of different molecular weights and concentrations are shown in 
Table 3.3.  
 
Table 3.3: Solubility of naphthalene in TRIS buffer solution with different concentrations and 
molecular weights of hyperbranched polymers 
 
Mn [Naphthalene] x 10
-4
 M 
1.00 x 10
-4 
M 2.00 x 10
-4 
M 4.00 x 10
-4 
M 6.00 x 10
-4 
M 
Without  polymer 0.58 0.58 0.58 0.58 
4000 1.20 1.30 1.86 2.26 
8500 1.59 1.98 2.11 2.36 
12500 1.79 2.44 2.56 2.90 
27500 2.70 3.23 3.47 4.48 
50000 2.91 3.94 4.49 6.28 
 
As a control, the complexation experiment was repeated without the hyperbranched 
polymers as discussed in Section 3.4.4. The solution was assessed by UV-Vis 
spectrophotometer,  and the calculated naphthalene concentration was 0.58 x 10
-4
 M, 
while as previously described (page 39), the maximum solubility of naphthalene has 
been recorded as high as 2.34 x 10
-4
 M.  
 
The amount of naphthalene encapsulated inside the hyperbranched polymer was 
calculated by taking the result from Table 3.3 and substracting  0.58 x 10
-4
 M from it,  
and all values are tabulated in Table 3.4 below. 
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Table 3.4: Amount of naphthalene encapsulated* in hyperbranched polymers 
 
Mn [Naphthalene] x 10
-4
 M 
1.00 x 10
-4 
M 2.00 x 10
-4 
M 4.00 x 10
-4 
M 6.00 x 10
-4 
M 
Without polymer 0.00 0.00 0.00 0.00 
4000 0.62 0.72 1.28 1.66 
8500 1.01 1.40 1.53 1.78 
12500 1.21 1.86 1.98 2.32 
27500 2.12 2.65 2.89 3.90 
50000 2.33 3.36 3.91 5.70 
*concentration after solubility of free naphthalene taken into account 
 
Overall, the results showed that the solubility of naphthalene increased after 
encapsulation with hyperbranched polymers. The solubility also increased with 
increasing molecular weight of the hyperbranched polymers. For example, for a 
molecular weight of 4000 Da, at polymer concentration of 1.00 x 10
-4 
M, the 
concentration is 0.62 x 10
-4
 M and it increased to 2.33 x 10
-4
 M for molecular weight of 
50000 Da. Similar trend applied to polymer concentration of 6.00 x 10
-4
 M, the 
naphthalene solubility increased from 1.66 x 10
-4
 M at polymer molecular weight of 
4000 Da to 5.70 x 10
-4
 M at 50000 Da. 
 
The increased polymer concentration also increased the solubility of naphthalene which 
was from 0.62 x 10
-4
 M at polymer concentration of 1.00 x 10
-4
 M to 1.66 x 10
-4
 M at 
polymer concentration of  6.00 x 10
-4
 M. If there is a linear relationship between 
polymer concentration and solubility of naphthalene, we should see the naphthalene 
concentration doubled at polymer concentration of  2.00 x 10
-4
 M, but this is not the 
case, which is clearly shown in Figure 3.16. 
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Figure 3.16:  Concentration of encapsulated naphthalene with a molecular weigtht of 
4000 Da and 50000 Da 
 
From the graph, it was clearly demonstrated that the polymer with molecular weight of 
4000 Da, the solubility of naphthalene increased up to polymer concentration of 2.00 x 
10
-4
 M, and it starts to flattened at polymer concentration of 6.00 x 10
-4
 M. The graph 
also showed that not much increased of naphthalene solubility at polymer concentration 
of 4.00 x 10
-4
 M and 6.00 x 10
-4
 M which were 1.28 x 10
-4
 M and 1.66 x 10
-4
 M 
respectively. This shows the polymer concentration of more than 4.00 x 10
-4
 M was not 
required. 
 
For polymer with molecular weight of 50000 Da, it was anticipated more solubilisation 
effect for bigger molecule, but it was not the case. At polymer concentration of 2.00 x 
10
-4
 M, the solubility of nahphtalene was 3.36 x 10
-4
 M and at polymer concentration of 
4.00 x 10
-4
 M, the model drug solubility was only 3.91 x 10
-4
 M and at polymer 
concentration of 6.00 x 10
-4
 M, the solubility of naphthalene was only 5.70 x 10
-4
 M. 
This indicates that the polymer concentration exceeding than 4.00 x 10
-4
 M is not 
required. 
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After discussing the effects of increasing concentrations of naphthalene with 
concentration of polymer, the discussion continued with the relation between two 
hyperbranched polymer concentrations, which were 2.00 x 10
-4
 M and 4.00 x 10
-4
 M 
with different molecular weights of the polymer. An investigation was made to 
determined wether an increased of the polymer molecular weight really effect the 
solubility of naphthalene. Figure 3.17 shows the relation between naphthalene 
concentration and different polymer molecular weights at hyperbranched polymer 
concentration of 2.00 x 10
-4
 M. 
 
Figure 3.17: Encapsulated naphthalene concentration with different molecular weights of 
hyperbranched polymer at polymer concentration of 2.00 x 10
-4
 M 
 
For polymer with a molecular weight of 4000 Da, the naphthalene concentration was 
0.72 x 10
-4
 M and it doubled at molecular weight of 8500 Da. However, at polymer 
molecular weight of 12500 Da, the naphthalene concentration was only 1.86 x 10
-4
 M, 
and at polymer molecular weight of 50000 Da, the naphthalene concentration was 3.36 x 
10
-4
 M. The naphthalene concentration increased until polymer molecular weight of 
8500 Da and plateaued at polymer molecular weight of 50000 Da.  
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Figure 3.18 shows the effect of increase of polymer molecular weight with naphthalene 
concentration at polymer concentration of 4.00 x 10
-4
 M. For polymer molecular weight 
of 4000 Da, the solubility of naphthalene was 1.28 x 10
-4
 M and at polymer molecular 
weight of 8500 Da, the solubility increased to 1.53 x 10
-4
 M.  
 
 
Figure 3.18: Encapsulated naphthalene concentration with different molecular weights of 
hyperbranched polymer at polymer concentration of 4.00 x 10
-4
 M 
 
At polymer molecular weight of 12500 Da, the naphthalene concentration rose to 1.98 x 
10
-4
 M. However, there was not much increased of naphthalene concentration when the 
molecular weight of the polymer increased until 50000 Da. From the above two graphs 
(Figure 3.17 and Figure 3.18), it was clearly shown that the polymer molecular weight 
of more than12500 Da gives less solubilisation effect for naphthalene. 
 
It was anticipated that the above situation might be due to the aggregation of the 
polymers and steric effect which prevent the guest molecules solubilised inside the 
hydrophobic voids of the polymers (Figure 3.19).                                       
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Figure 3.19: Aggregation of the hyperbranched polymers 
 
A better view of the solubilisation behaviour for all samples are shown in Figure 3.20. It 
can be seen from the bar graph, that before encapsulation, the solubility of naphthalene 
is zero (after free solubility of naphthalene taken into account), and increases drastically 
after encapsulation with the host molecule. For example, for a host molecular weight of 
8500 Da and concentration of 1.00  x 10
-4
 M, the concentration of naphthalene increased 
to 1.01 x 10
-4
 M. The concentration rose gradually to a host concentration of 6.00 x 10
-4
 
M. This trend also applies to the increasing concentration of guest molecule with the 
increasing molecular weights of the host.  
 
 
Figure 3.20: Increasing Mn and concentration of hyperbranched polymers with 
increasing concentrataion of encapsulated naphthalene 
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The data obtained show that these hyperbranched polymers have the ability to 
encapsulate guest molecules within their hydrophobic voids. A higher molecular weight 
resulted in higher loading of naphthalene. The loading per mole of polymer was 
calculated by dividing the concentration of naphthalene by the concentration of polymer. 
Different molecular weight resulted in different loading of guest molecule, for example, 
hyperbanched polymers with a concentration of 1.00 x 10
-4
 M, as shown in Table 3.5. 
Every mole of polymer with Mn 4000 Da can only encapsulate 1 mole of naphthalene. 
The number of moles of naphthalene increased to 2 for Mn 50000 Da. This shows that 
increasing molecular weight will increased the loading per mole of naphthalene in 
hyperbranched polymers. 
 
Table 3.5: Naphthalene loading per mole of hyperbanched polymers  
with concentration of 1.00 x 10
-4
 M 
 
Mn Absorption [Naphthalene] 
(x 10
-4
)M 
Loading 
4000 0.1298 0.62 1 
8500 0.2117 1.01 1 
12500 0.2539 1.21 1 
27500 0.4499 2.12 2 
50000 0.4910 2.33 2 
 
 
Figure 3.21 shows part of a polymer with a molecular weight of 3000 g mol
-1
. From this 
theoretical diagram, it can be seen that the polymer can be filled with around ten 
molecules of naphthalene. However, Table 3.5 shows that only one naphthalene 
molecules was encapsulated in the polymer. For a larger Mn of polymer, the results 
showed that only two naphthalene molecules were trapped inside the hyperbranched 
polymers. This may be due to the physical property of naphthalene, a very hydrophobic 
molecule with two fused benzene rings, which only permit a small number of these 
molecules to be trapped in the cavities of the hyperbranched polymers. Other possibility 
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is the steric effect of the polymers which allows small amount of naphthalene trapped 
inside its’ cavities. 
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Figure 3.21: A representation of polyglycerol with naphthalene within the voids 
 
3.4.6 Encapsulation of ibuprofen with hyperbranched polymers 
The second molecule used to investigate the ability of hyperbranched polymers to 
solubilise hydrophobic moieties is ibuprofen. Ibuprofen is a non-steroidal anti- 
inflammatory drug widely used for pain and fever treatment. This drug has a molecular 
weight of 206.28 g mol
-1
 and is detected at λmax = 222 nm. It has a polar and ionisable 
carboxylic acid functional group which gives it partial solubility in water (less than  4.80 
x 10
-3
 M). Although this drug is widely used in modern medicine, ibuprofen is not free 
of disadvantages. One of its side effects is aggravation of the stomach lining, leading to 
stomach ulceration and bleeding. Encapsulation of ibuprofen with these potential 
hyperbanched polymers may reduced the risk of side effects when administered into the 
human body.  
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Encapsulation using ibuprofen was carried out using the same method as discussed in 
Section 3.4.4.1 (page 38). The absorbance peak was to strong as absorbance needs to be 
observable by UV, and therefore was diluted 50 fold and the absorbance was assessed at 
its characteristic wavelength. The initial concentration was calculated by dividing the 
actual absorbance by the extinction coefficient (ε) of ibuprofen. The extinction 
coefficient value was obtained graphically from a Beer Lambert plot as 8387.5 M
-1 
cm
-1
. 
It was then multiplied by 50 to get the concentration as shown in Table 3.6 below. 
 
Table 3.6: Solubility of ibuprofen in TRIS buffer solution with different concentrations and 
molecular     weights of hyperbanched polymers 
 
Mn [Ibuprofen] x 10
-4
 M 
1.00 x 10
-4 
M 2.00 x 10
-4 
M 4.00 x 10
-4 
M 6.00 x 10
-4 
M 
Without polymer 2.68 2.68 2.68 2.68 
4000 7.98 8.75 9.20 10.39 
8500 8.08 9.60 11.24 12.57 
12500 8.83 10.35 15.63 18.63 
27500 10.13 12.77 18.80 21.25 
50000 15.56 16.97 21.89 23.14 
 
To calculate the exact amount of ibuprofen encapsulated in the hyperbranched polymers, 
a complexion without the hyperbranched polymers was prepared. Excess ibuprofen was 
dissolved in water and filtered. The solution was measured using UV and the value 
obtained was 2.68 x 10
-4
 M. This amount was calculated by taking the result from Table 
3.6 and substracting 2.68 x 10
-4
 M from it and the new data is shown in Table 3.7 
below. 
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Table 3.7: Amount ibuprofen encapsulated* in the hyperbranched polymers 
 
Mn [Ibuprofen] x 10
-4
 M 
1.00 x 10
-4 
M 2.00 x 10
-4 
M 4.00 x 10
-4 
M 6.00 x 10
-4 
M 
Without polymer 0.00 0.00 0.00 0.00 
4000 5.30 6.07 6.53 7.71 
8500 6.07 7.00 8.56 9.89 
12500 6.15 7.67 12.95 12.95 
27500 7.45 10.09 16.12 18.57 
50000 12.88 14.29 19.21 20.46 
*Concentration after free ibuprofen solubility taken into account 
 
From the above table, it can be seen that the concentration of ibuprofen increased with 
increasing concentrations and molecular weights of the polymer. For a better view of the 
discussions, we chose hyperbranched polymers with a molecular weight of 4000 Da and 
50000 Da, as shown in Figure 3.22.  
 
Figure 3.22: Increased encapsulated ibuprofen concentration with increased molecular weights 
and concentrations of hyperbranched polymers 
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For hyperbranched polymers with a molecular weight of 4000 Da, the concentration of 
ibuprofen rose after encapsulation with a hyperbranched polymer with a concentration of 
2.00 x 10
-4
 M and after this point, there was not much increased in ibuprofen 
concentration. The same pattern was also detected for a hyperbranched polymer with a 
molecular weight of 50000 Da. If we look carefully, the trendline increased gradually at 
polymer concentration of 2.00 x 10
-4
 M and plateaued at 6.00 x 10
-4
 M. It was clearly 
shown  that polymer concentration of more than 4.00 x 10
-4
 M is not required.  
 
To investigate the maximum polymer molecular weight for solubilising ibuprofen, a 
graph of encapsulated ibuprofen concentration versus different polymer molecular 
weights is plotted as shown in Figure 3.23.  
 
 
Figure 3.23: Encapsulated ibuprofen concentration with different molecular weights of 
hyperbranched polymer at hyperbranched polymer concentration of 2.00 x 10
-4
 M 
 
The above graph demonstrated the relation between encapsulated ibuprofen  
concentration with different polymer molecular weights at hyperbranched polymer 
concentration of 2.00 x 10
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-4
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weight of 12500 Da. After polymer molecular weight of 12500 Da, there was no 
significant increased in ibuprofen concentration. 
 
Figure 3.24 showed the encapsulated ibuprofen concentration with different molecular 
weights of hyperbranched polymer at polymer concentration of 4.00 x 10
-4 
M. The graph 
shows the same trend as previous graph, where, the ibuprofen concentration increased to 
12.95 x 10
-4
 M at polymer molecular weight of 12500 Da and not much increased in 
ibuprofen concentration (19.21 x 10
-4
 M) at polymer molecular weight of 50000 Da. It 
was postulated that the polymers experienced an aggregation and become more 
significant at higher molecular weight. 
 
 
Figure 3.24: Encapsulated ibuprofen concentration with different molecular weights of 
hyperbranched polymer at hyperbranched polymer concentration of 4.00 x 10
-4
 M 
 
Illustration of the behaviour of the solubilisation effect on different polymer 
concentrations and molecular weights are shown in Figure 3.25. The concentration of 
encapsulated ibuprofen increased with increasing polymer concentration and molecular 
weight. From the bar graph below, for a hyperbranched polymer with a molecular 
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50000 Da, the highest concentration of ibuprofen was 20.46 x 10
-4
 M. This could be due 
to the formation of hydrogen bonds between the carboxylic group of ibuprofen and the 
interior of the polymers. 
 
Figure 3.25: Increased concentration of encapsulated ibuprofen after encapsulation with 
different concentrations and molecular weights of hyperbranched polymer 
 
As previously discussed, the concentration of ibuprofen increased gradually and 
plateaued at a polymer concentration of 6.00 x 10
-4
 M. From the results, the loading of 
ibuprofen per mole of polymers can be calculated. The loading was defined by dividing 
the concentration of ibuprofen with the concentration of polymer. Table 3.8 below 
shows the loading of ibuprofen if only 1.00 x 10
-4
 M polymers were consumed. The 
loading increased with an increase in molecular weights of the hyperbranched polymers. 
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Table 3.8: Ibuprofen loading per mole of hyperbranched polymers with a concentration 
1.00 x 10
-4
 M 
 
Mn Absorption [Ibuprofen] 
(x 10
-4
) M 
Loading 
4000 0.1338 5.30 5 
8500 0.1355 6.07 6 
12500 0.1482 6.15 6 
27500 0.1700 7.45 7 
50000 0.2611 12.88 13 
 
The encapsulation of ibuprofen within the cavities of the hyperbranched polymers is 
illustrated below in Figure 3.26. This figure reveals only a part of the hyperbranched 
polymers to show the entrapment of ibuprofen. From Table 3.8, the loading of ibuprofen 
per mole of polymer was 5 for the lowest molecular weight, increasing to 13 for 
polymers with a molecular weight of 50000 Da. More ibuprofen was trapped in the 
cavities of the hyperbranched polymers due to the formation of hydrogen bonds between 
the interior of the hyperbranched polymers and the carboxylic groups of ibuprofen.  
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Figure 3.26: Ibuprofen filled into a hyperbranched polymer 
 
As ibuprofen has some solubility in water therefore the signal can be detected by the 
NMR instrument, so this technique was used to prove the complex formation within the 
hydrophobic voids of hyperbranched polymers. Figure 3.27 shows the spectrum of a 
simple mix of ibuprofen and hyperbranched polymers, and Figure 3.28 reveals the 
spectrum of ibuprofen after being encapsulated within the polymers.  
 
In Figure 3.27, the broad peak from 4.00 to 3.25 ppm can be attributed to the 
hyperbranched polymer backbone whereas the peaks at 2.32, 1.23 and 0.71 ppm refer to 
ibuprofen peaks. Significantly, the ibuprofen intensity peaks increased around 20 % 
when the drug formed a complex with the hyperbranched polymer. The concentration of 
ibuprofen rose from 2.68 x 10
-4
 M to 3.12 x 10
-4
 M with polymer concentration of 1.00 x 
10
-4
 M. This is shown in Figure 3.28. The hyperbranched polymer peak was normalised, 
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so that the peak are the same size. Therefore, any increases in ibuprofen peaks are due to 
the increased in ibuprofen solubility. 
 
 
Figure 3.27: 
1
H NMR spectrum of mixing of ibuprofen with hyperbranched polymer in D2O 
 
 
Figure 3.28: 
1
H NMR spectrum of complexation of ibuprofen with hyperbranched polymers in 
D2O 
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In conjunction  with UV studies that hyperbranched polymers can enhance the solubility 
of ibuprofen. From this promising data, further investigation was carried out using a 
bigger molecule, from the porphyrin group, i.e. tetracarboxyphenyl porphyrin (TCPP). 
TCPP was encapsulated with the hyperbranched polymers. This model drug has been 
studied extensively in the application of cancer treatment. 
 
3.4.7  Photodynamic therapy 
Photodynamic therapy (PDT) is a promising clinical tumour treatment, especially for the 
treatment of digestive tract, skin, bladder, respiratory and head and neck cancers. PDT is 
based on the induction of cell death by the administration of special drugs known as  
photosensitisers (PS) which selectively accumulate in the tumour tissue, followed by 
subsequent exposure to light of an appropriate wavelength and the presence of 
oxygen.
51-53 
The advantages of PDT compared to conventional methods are that it has 
very low systemic toxicity, PS is only activated in the presence of light, it has the ability 
to selectively destroy the tumours and PDT can be used alone or in combination with 
other therapeutic modalities such as chemotherapy, radiotherapy, immunotherapy or 
surgery.
54  
However, the rest of the body must be protected from light (unless the PS 
only accumulates in the tumour). 
 
3.4.7.1  Mechanism of photodynamic therapy 
The main factors that plays an important role in PDT are the photosensitisers, the radical 
singlet oxygen (
1
O2) and the delivery of light source. The basic routes by which the 
combination of photosensitizer (PS), light and O2 are delivered are shown in Figure 
3.29. A ground state of PS contains two electrons of opposite spins at a low energy 
molecular level, known as the singlet state (S0). This non-excitation state of PS absorbs 
visible light (photons) and shifts to an electronically excited singlet state (S1). This state 
is short lived and loses its energy by emitting fluorescent light. The excited singlet state 
PS may also undergo a process known as intersystem crossing, where the excited 
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electron converts to a long-lived triplet excitation state (T1) and its energy is dissipated 
by emitting phosphorescent light.  
 
The PS in a triplet excitation state can undergo two types of reaction. Firstly, PS reacts 
directly with molecules to form various species of hydrogen atom or an electron, or 
generates radicals that interact with the oxygen atom to produce a reactive oxygen 
species (ROS), which are toxic to all cells. In the other reaction, PS transfers its energy 
directly to the ground state molecular oxygen to form an excited state singlet oxygen 
(
1
O2).
51-59
 The latter reaction is an important indicator of successful PDT.  
 
 
 
Figure 3.29: Photodynamic therapy mechanism 
 
In the early stages of the PDT experiment, the photosensitisers used were 
haematoporphyrin (HP) and its derivative (HPD) which is a mixture of mono-, di- and 
oligomers of porphyrin. A photosensitizer suitable for PDT should have several 
characteristics including chemical purity, selectivity for tumour cells, chemical and 
physical stability, a short time interval between administration and maximum 
accumulation within tumour tissues, activation of wavelengths with optimal tissue 
penetration and be easily removed from the body. The four main classes of 
photosensitisers are porphyrin derivatives, chlorins, phthalocyanines and porphycenes.
51
 
These photosensitisers are directly administered into the body and ideally they 
accumulate in the affected cancerous area.  
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However, this is not always the case. A mechanism known to help with accumulations 
of molecules within tumors is the enhanced permeability and retention (EPR) effect. The 
EPR effect is a phenomenon whereby a certain size of a molecule, especially big 
molecules such as macromolecules and nanoparticles, tend to accumulate in tumour 
tissue. These occur when tumour cells undergo aggregation and new blood vessels are 
produced to fulfil oxygen and nutrient demands from the tumour cell. This new blood 
vessel has an irregular in shape and openings at the cell surface. These big molecules are 
not easily removed and they are retained in the tumour.
60-63
 Figure 3.30 illustrates the 
EPR effect. 
 
           macromolecules  
 
 
          blood vessel 
           
 
        small molecule 
 
Figure 3.30: Schematic representation of the EPR effect 
 
The following discussion will point out the importance of this effect in designing a big 
drug delivery system, which consists of a porphyrin derivative and is encapsulated 
within hyperbranched polymers with different molecular weights. 
 
3.4.5.2 Synthesis of tetracarboxyphenyl porphyrin (TCPP) 
Tetracarboxyphenyl porphyrin (TCPP) (Scheme 6) was synthesized by refluxing 4-
carboxy benzaldehyde and pyrrole in propionic acid. The black slurry mixture was 
filtered and then washed with refluxing dichloromethane. The product obtained was a 
deep purple crystal. Confirmation of the product was achieved using 
1
H NMR, UV-vis 
Tumor cell 
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spectrometer, mass spectrometer and CHN analysis. A singlet  was  observed at 8.86 
ppm  and was assigned to the pyrrolic β-protons. A quartet peak was seen around 8.23 
ppm and was attributed to the 16 phenyl protons. The highly shielded -NH protons were 
seen at -2.95 ppm. A singlet peak at 13.32 ppm was due to the 4 protons attached to the 
carboxylic group. Mass spectrometry showed the exact molecular ion with M/z of 791. 
UV-Vis spectrophotometry revealed characteristic peaks at λmax = 412, 512, 546, 588 
and 645 nm. 
NH NH
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OH
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Scheme 6 : Synthesis of tetracarboxyphenyl porphyrin 
 
3.4.7.3 Encapsulation of tetracarboxyphenyl porhyrin with hyperbranched 
polymers  
 
The third model drug used was tetracarboxyphenyl porphyrin. This model drug has a 
molecular weight of 791.44 gmol
-1
 and was synthesised successfully using chemicals 
available in the laboratory. Encapsulation of tetracarboxyphenyl porphyrin was done 
using four different polymer concentrations and and five different molecular weights. 
The complexes were added to TRIS buffer at pH 7.4 at 0.1 M. The absorbance of all 
solutions was recorded using a UV-vis spectrophotometer. A strong porphyrin peak was 
detected at λmax = 415 nm. The purple red colour of porphyrin can be seen by the naked  
eye, and several dilutions were needed to reduce the concentration and ascertain the 
correct absorbance for the sample. For hyperbranched polymers with molecular weights 
of 4000 Da and 8500 Da, dilutions were made 100 fold. For polymers with molecular 
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weights of 12500 Da, 27500 Da and 50000 Da, 200 fold dilutions were performed to 
record the suitable spectra.  
 
TCPP concentration was determined by dividing the absorbance from  raw UV data by 
the standard extinction coefficient (ε) of TCPP which was calculated as 3.30 x 105 M-1 
cm
-1
. This value was then multiplied by the number of dilutions made to determine the 
concentration of TCPP. The values of different concentrations and molecular weights 
are tabulated  in Table 3.9. 
 
Table 3.9: Solubility of tetracarboxyphenyl porphyrin in TRIS buffer solution with different 
concentrations and molecular weights of hyperbanched polymers 
 
Mn [Tetracarboxyphenyl porphyrin] x 10
-4
 M 
1.00 x 10
-4 
M 2.00 x 10
-4 
M 4.00 x 10
-4 
M 6.00 x 10
-4 
M 
Without polymer 0.72 0.72 0.72 0.72 
4000 2.09 2.61 3.44 3.61 
8500 2.43 3.21 3.60 3.79 
12500 3.48 5.19 8.32 9.92 
27500 4.69 7.92 9.12 10.17 
50000 5.73 9.04 10.55 11.65 
  
As a control, the solubility of TCPP in water was determined by dissolving an excess 
amount of TCPP in water. All undissolved TCPP was filtered. The solution was 
measured using UV and the absorbance was divided by the extinction coefficient 
constant; the value was 0.72 x 10
-4
 M. The amount of TCPP encapsulated in the 
hyperbranched polymer (Table 3.9)  was subtracted with  0.72 x 10
-4
 M; the data is 
shown below in Table 3.10. 
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Table 3.10: Amount of TCPP encapsulated* inside hyperbranched polymer 
 
Mn [Tetracarboxyphenyl porphyrin] x 10
-4
 M 
1.00 x 10
-4 
M 2.00 x 10
-4 
M 4.00 x 10
-4 
M 6.00 x 10
-4 
M 
Without polymer 0.00 0.00 0.00 0.00 
4000 1.39 1.91 2.74 2.91 
8500 1.73 2.51 2.90 3.09 
12500 2.78 4.49 7.62 9.22 
27500 3.99 7.22 8.42 9.47 
50000 5.03 8.34 9.85 10.95 
 *Concentration after free TCPP taken into account 
 
The results showed that the concentration of TCPP increased with increased 
concentration of hyperbranched polymers. The behaviour of these encapsulation 
experiments is depicted in Figure 3.31. For hyperbranched polymers with a molecular 
weight of 4000 Da, TCPP concentration increased up to a polymer concentration of 2.00 
x 10
-4
 M and became plateaued at a polymer concentration of 6.00 x 10
-4 
M. The same 
pattern applied to a polymer with a molecular weight of 50000 Da.  
 
 
Figure 3.31: Encapsulated TCPP concentration for molecular weight of 4000 Da and 
50000 Da 
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A closer look at the above graph showed that there was not much increased in TCPP 
concentration above polymer concentration of 4.00 x 10
-4
 M. To investigate the effect of 
the polymer molecular weight in solubilising TCPP, a graph between TCPP 
concentration with different polymer molecular weights at  hyperbranched polymer 
concentration of 2.00 x 10
-4
 M and 4.00 x 10
-4
 M were plotted in Figure 3.32 and 
Figure 3.33 respectively. 
 
Figure 3.32 showed  the TCPP concentration was 1.91 x 10
-4
 M at polymer molecular 
weight of 4000 Da and it increased to 4.49 x 10
-4
 M at polymer molecular weight of 
12500 Da. Further increased in polymer molecular weight did not make any significant 
changes in TCPP concentration.  
 
 
Figure 3.32: Encapsulated TCPP concentration of 2.00 x 10-4 M with different molecular 
weights of hyperbranched polymer 
 
Figure 3.33 demonstrated encapsulated TCPP concentration at various polymer 
molecular weights at hyperbranched polymer concentration of 4.00 x 10
-4
 M. The same 
trend was observed, where TCPP concentration increased to 7.62 x 10
-4
 M at polymer 
molecular weight of 12500 Da, and only a small increment of TCPP concentration at 
50000 Da.  
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0 10000 20000 30000 40000 50000 
[T
C
P
P
] 
x
 1
0
-4
 M
 
Molecular weight (Mn) 
79 
 
 
Figure 3.33: Encapsulated TCPP concentration of 4.00 x 10-4 M with different molecular weight 
of hyperbranched polymer 
 
From the above observation, for both hyperbranched polymer concentrations used (2.00 
x 10
-4
 M and 4.00 x 10
-4
 M), the polymer molecular weight of above 12500 Da did not 
showed any significant difference in  solubilising TCPP. This trend might be due to 
aggregation of polymers at higher concentration. 
 
Further evidence for these results is depicted in Figure 3.34. It can be seen in the bar 
graph, that TCPP concentration increased after encapsulation with each molecular 
weights used in these studies. TCPP concentration also increased with increased 
polymer concentration. Let’s take a closer look at polymers concentration of 1.00 x 10-4 
M and 6.00 x 10
-4
 M with different molecular weights. For a polymer concentration of 
1.00 x 10
-4 
M and a molecular weight of 4000 Da, TCPP concentration was 1.39 x 10
-4
 
M and this almost tripled at a molecular weight of 50000 Da, at 5.03 x 10
-4
 M. The same 
pattern applied to a polymer concentration of 6.00 x 10
-4
 M and a molecular weight of 
4000 Da: TCPP concentration was 2.91 x 10
-4
 M and increased to 10.95 x 10
-4
 M at 
50000 Da. From these observations, it was concluded that higher molecular weights give 
higher concentrations of TCPP.   
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Figure 3.34: Increased concentration of encapsulated TCPP after encapsulation with 
different concentrations and molecular weights of hyperbranched polymer 
 
Even though the concentration increased with increased molecular weight of the 
hyperbranched polymers,  there was no real changes from a molecular weight of 12500 
Da to 50000 Da. They reached a limit at 12500 Da and 12500 Da could be the best 
molecular weight to encapsulate TCPP. There was not much increased for 50000 Da 
with respect to solubility, but this might be useful in the delivery systems, as size is 
important factor in the EPR effect. 
 
In order to calculate the TCPP loading per mole of polymer, one polymer with a 
concentration of 1.00 x 10
-4
 M was selected. Loading per mole of TCPP in polymers was 
obtained by dividing the TCPP concentration after encapsulation with the polymer 
concentration. For this purpose, hyperbranched polymers with a concentration of 1.00 x 
10
-4
 M were used as the model of calculation. All values are shown in Table 3.11. 
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Table 3.11: Tetracarboxyphenyl porphyrin loading per mole of hyperbranched polymers 
with concentration of 1.00 x 10
-4
 M 
 
Mn Absorption [TCPP] 
(x 10
-4
)M 
Loading 
4000 0.6918 1.39 1 
8500 0.8019 1.73 2 
12500 0.5755 2.78 4 
27500 0.7741 3.99 4 
50000 0.9454 5.03 5 
                   
The results show that, only one mole of porphyrin was encapsulated within the cavities 
of the polymer at 4000 Da. At a molecular weight of 50000 Da, only five moles of TCPP 
can be accommodated in the polymer dendritic box. This value is quite reasonable, 
because TCPP is a big molecule and has carboxylic groups attached to the main 
molecule. The carboxylic group may interact with the interior of the polymers. Other 
possibility is the steric effect between the polymer and TCPP. Figure 3.35 represents a 
portion of a hyperbranched polymers filled with some porphyrin molecules, which 
indicates that the numbers obtained in Table 4.9 are realistic. 
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Figure 3.35: Tetracarboxyphenyl porphyrin filled in hyperbranched polymers 
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A further investigation was done using a real drug to combat prion disease. This drug 
was synthesized by other group in the department (Dr Chen’s group) Therefore, the 
following discussion is about encapsulation of the antiprion drug with hyperbranched 
polymers. 
 
3.4.8: Encapsulation of hyperbranched polymers with an anti-prion drug for prion 
therapy application 
 
3.4.8.1  Prion Disease  
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a 
group of animal and human brain diseases.
64
 TSEs in humans include Creutzfeldt-Jakob 
disease (CJD), kuru, Gerstmann-Straussler-Scheinker Syndrome (GSS), fatal familial 
insomnia (FFI) and new variant JCD (nvCJD). These diseases are predominantly 
inherited by 10% of sufferers, and less than 1% are acquired by infection. The disease 
also affects sheep and goats, cats, pumas and cheetahs.
64
 All prion diseases are 
progressive, fatal and presently incurable. Prion disease is associated with the 
accumulation of prion protein in the brain.
65-66
 Prions are infectious agents, composed of 
misfolded protein. When this happens, protein aggregates and has a toxic effect on the 
adjacent protein.  
3.4.8.2 Anti-prion drug 
After unsuccessful attempts  to make collaboration with other university to evaluate the 
performance of our hyperbranched polymer. It was found that the evaluation was not 
what we required. Therefore a collaboration with Dr Chen’s group in our department. 
This group eventually synthesised drugs for prion disease. The anti-prion drug is shown 
below in Figure 3.36. 
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Figure 3.36: Anti-prion drug used in encapsulation study 
The drug synthesis was a good antiprion drug but is insoluble in water. Therefore, we  
proposed to encapsulate this drug with our hyperbranched polymers. The following 
discussions is about our investigation of the performance of hyperbranched polymers in 
complex formation with the anti-prion drug. 
 
3.4.8.2 Complex formation of anti-prion drug with hyperbranched polymers 
The previous drugs and models were encapsulated using different molecular weights and 
concentrations. However, for prion therapy studies, only one polymer was selected 
hyperbranched polymers with a molecular weight of 12500 Da. This polymer was 
chosen because previous results showed that hyperbranched polymers with a molecular 
weight of 12500 Da give the best encapsulation outcome. This anti-prion drug does not 
dissolve in water. Therefore, to evaluate the characteristic peak of the drug, excess drug 
was dissolved in methanol and filtered to separate the undissolved drug. The solution 
was measured using a UV-Vis spectrophotometer, and the peak was at 335 nm, as 
shown in Figure 3.37. Methanol was used as the solvent because it has a similar polarity 
as water. 
 
 Not soluble in water  
 EC50 = 10 nm in DMSO 
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Figure 3.37: UV spectra of anti-prion drug in methanol 
The anti-prion drug used is completely insoluble in water: therefore, it was interesting to 
explore how this hyperbranched polymer could effectively encapsulate the drug. Both 
drug and polymer were dissolved separately in methanol. Both solution were then 
physically mixed and all solvents removed in vacuo to form co-precipitation. Water was 
then added and finally the solution was filtered to remove any undissolved drug. The 
active compound in the sample was detected using a UV-Vis spectrophotometer. The 
spectrum is shown in Figure 3.38. 
 
Figure 3.38: UV spectra of a hyperbranched polymer in water, an antiprion drug in 
methanol and encapsulation of the drug with a hyperbranched polymer 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
280 380 
A
b
so
rb
a
n
ce
 
wavelength (nm) 
0 
0.5 
1 
1.5 
2 
2.5 
260 280 300 320 340 360 380 400 420 440 
A
b
so
rb
a
n
ce
 
wavelength (nm) 
Encapsulated drug inside polymer 
Polymer in water 
Drug in methanol 
85 
 
 
The hyperbranched polymer peak was detected at 310 nm. A shoulder peak was clearly 
observed in the encapsulated spectra at 330 nm. The concentration of encapsulated drug 
can be calculated by dividing the absorbance of the drug by the standard extinction 
coefficient (ε) of the drug. The standard extinction coefficient of the drug was 
determined using a Beer Lambert plot which and was 19155 M
-1
cm
-1
.  After calculation, 
the concentration of the drug increased to 9.02 x 10
-5
 M. The concentration of polymers 
used in these study was 3.42 x 10
-4
 M. This was clearly proof, that hyperbranched 
polymers can solubilised hydrophobic molecules inside their hydrophobic voids. 
Loading per mole of drug that can be encapsulated inside the polymers was obtained by 
dividing the polymer concentration by the drug concentration. From the calculation, only 
0.27 mole of drug was encapsulated inside the hyperbranched polymers. 
 
3.4.8.3 Cytotoxicity  Studies 
This study was carried out with the collaboration of  Mr Luo Lei, a member from Dr 
Chen’s group. To determine whether these hyperbranched polymers can behave as a 
delivering agent, a cytotoxicity test was carried out. This test was done using MTT assay 
against a cultured scrapie mouse brain cell. The MTT assay is based on the ability of a 
mitochondrial dehydrogenation enzyme in viable cells to cleave the tetrazolium rings of 
the pale yellow MTT and form formazon crystals with a purple colour.
67
 Therefore, the 
number of surviving cells is directly proportionate to the level of the formed formazon. 
The MTT assay of all hyperbranched polymers with three different  concentrations, 100 
μM, 500 μM and 1000 μM, are depicted in Figure 3.39. As shown in the bar chart, all 
polymers were not toxic against the scrapie mouse brain (SMB) cell. 
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Figure 3.39: UV spectra of a hyperbranched polymer in water, an antiprion drug in 
methanol and encapsulation of the drug with a hyperbranched polymer 
 
EC50 of a drug denotes as measurement of the concentration of drug which gives 50% of 
the maximum response.
68 
Even though the EC50 of the drug against the SMB cell is 10 
nm, it is in DMSO, whereas the EC50 of the drug encapsulated in the hyperbranched 
polymer is 0.693 μM, but it is in water (Figure 3.40). From this premilinary studies, it is 
concluded that hyperbranched polymers have the ability to bind drugs inside their 
hydrophobic voids. We proposed that the mechanism of solubility enhancement is due to 
the hydrophobic interaction between the drug and moieties inside the hyperbranched 
polymers. 
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Figure 3.40: The EC50 of the drug encapsulated with hyperbranched polymers 
 
From all the above results, starting from synthesising water soluble hyperbranched 
polymer, encapsulation studies with model drugs and drug and finally the toxicity test 
showed the water soluble hyperbranched polymer is a promising candidate as drug 
delivery system. 
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Chapter 4: Synthesis and Characterization of Hyperbranched 
Polyglycidol Conjugated with Poly(ethylene) Glycol and Folic Acid 
(PG-PEG-Folate) 
 
4.1 Overview and aim 
Cancer is a common disease in the modern world. More than one in three people will 
develop some form of cancer during their lifetime. Diet, lifestyle and environment are 
major factors that cause this disease. Most drugs for cancer treatment have very poor 
solubility in water. This, and their instability in a biological environment make it 
difficult to deliver them to specific sites in safe dosages.
36
 
 
 Camptothecin, 12 (Figure 4.1) has been widely used to treat various types of cancer but 
can damages DNA, leading to cell destruction. This drug has very low solubility in 
water and it’s side effect is inflammation of the urinary bladder. In order to overcome 
these problems, this drug has been conjugated with  liposomes, micelles and emulsions. 
Cisplatin, 13, also has some effects when introduced into the human body. The 
formation of stable DNA-cisplatin complexes, resulting in the formation of a DNA 
structure that prevents replication.  
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Figure 4.1: Anticancer drugs: Camptothecin (12), Cisplatin (13) and doxorubin (14) 
 
Another anticancer drug, doxorubin, 14, has been widely used to treat leukaemia, 
Hodgkin’s lymphoma and cancers of the bladder, breast, stomach, lung, ovaries and 
89 
 
thyroid. In order to enhance drug solubility in water, cisplatin has been encapsulated 
with liposomes (trade name Doxil
®
).
36,69-71
 
 
A major drawback of anticancer drugs is they easily attack healthy cells as well as 
cancerous cells. However, these harmful side effects can be reduced by developing drug 
carriers which can take the drug directly to the specific targeted tumour site. Dendritic 
polymers such as dendrimers and hyperbranched polymers are suitable as potential 
carriers in drug delivery applications. Apart from drug delivery, these macromolecules 
can be extended to targeting via functionalisation, as shown in Figure 4.2. 
                                                                                    
 
 
 
 
Figure 4.2: Cartoon of dendrimers with targeting entity 
In cancer treatment, the folate receptor (FR) has been known to be over-expressed in 
several human tumours such as in the kidney, breast, lung and brain.  FR density also 
appears to increase with advancing stages of the cancer.
72-80 
Exploiting the above-
mentioned facts, it is hypothesized that folate conjugation to dendritic polymers could 
improve the accumulation of drugs at the tumour site and enhanced the possibility of 
killing the cancer cells.
81
 A better picture of the above is depicted in Figure 4.3 below. 
 
 
 
 
 
Targeting entity 
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FR – folic receptor 
FA – folic acid 
                                                              
Figure 4.3: Schematic functionalisation of folic acid via a spacer with a polymer 
In this chapter, the subject will be hyperbranched polymers with the targeting ability of a 
folate receptor. This can be achieved by conjugating folic acid with hyperbranched 
polymers via poly (ethylene) glycol as a spacer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tumor cell 
spacer 
   FR  FA polymer 
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4.2 Results and discussion 
Conjugation of folic acid through a polyethylene glycol (PEG) spacer with 
hyperbranched polyglicidol (PG) was achieved by employing several steps before the 
final product was produced. Initially, folic acid was activated by N- hydroxysuccinimide 
(NHS) to produce an NHS ester of folic acid (FA-NHS) (Scheme 4.1).
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Scheme 4.1 : Synthesis of FA-NHS  
The synthesis of folic acid ester was very crucial as these step was very important before 
polyethylene (glycol)  could be conjugated with folic acid. In Scheme 4.1, NHS will 
convert folic acid to an ester compound and NHS is a good leaving group. These leaving 
group was essential for conjugation with PEG. To the above reaction, N,N’dicyclohexyl 
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carbodiimide was added as a coupling agent. Such a long period have been used to make 
these compound and many attempts have been made to get an appropriate method. 
Several different temperatures were tried, different durations of experiment, 
modification to the reagent and using different solvents. Through all the experiments, 
experience was gained in handling the compound. Another challenging step was to 
reduce DMSO concentration using a very specific apparatus. 
Folic acid is known to have a good targeting ligand, and therefore it is suitable for these 
proposed targeting design. Folic acid can be conjugated with hyperbranched polymers 
through two approaches: direct and indirect conjugation. In this work, indirect 
conjugation was chosen, which used a folic acid ester and was then conjugated with 
poly(ethylene glycol) (PEG)3000 bis amine (NH2-PEG3000-NH2) to produce a 
conjugated folic acid ester with PEG bis amine as the spacer. The schematic reaction 
was shown below in Scheme 4.2. 
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Scheme 4.2 : Synthesis of Folate - PEG-NH2  
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Prior to the preparation of the hyperbranched polymer conjugated with folate-PEG-NH2, 
it was first activated with succinic anhydride to produce polyglycidol - succinic 
anhydride (PG-SA) (Scheme 4.3).
89-92
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Scheme 4.3: Synthesis of PG-SA
125oC
 
The final step was conjugation of PG-SA with folate-PEG-NH2 to produce polyglycidol-
poly (ethylene glycol)-folate (PG-PEG-Folate) shown in Scheme 4.4.
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The above ideas were transferred into actual experiments by combining and/or 
substracting ideas taken from the literature, finally, the series of experiments developed 
listed below : 
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 Step 1- synthesis of polyglicidol  succinic anhydride (PG-SA) 
 Step 2- synthesis of folic acid ester (FA-NHS) 
 Step 3- synthesis of folate-poly(ethylene glycol) bis amine (Folate-PEG-NH2) 
 Step 4- synthesis of polyglicidol-folate-poly(ethylene glycol) (PG-Folate-PEG 
 
4.2.1  Step 1: Synthesis and characterization of polyglycidol-succinic anhydride 
(PG-SA) 
Initially, the hydroxyl end group of polyglycidol was converted to a carboxyl end group 
(PG-SA) (Scheme 4.3). This compound was synthesised by dissolving hyperbranched 
polyglicidol (PG) with dry MeOH, and succinic anhydride was added. This PG was 
synthesised by ring-opening polymerisation of glycidol as the monomer and p-
nitrophenol as the core. The mixture was stirred continually for 48 hours at a 
temperature of 125 
o
C. Purification of the product was carried out by precipitation with 
ethanol three times. The final product was a viscous yellow solid. The product was 
characterised using 
1
H NMR, as shown in Figure 4.4. A broad peak was observed in the 
range of 4.33 – 3.21 ppm, corresponding to the abundance of protons in the polymer 
backbone of polyglycidol. One broad singlet at 2.54 ppm could be attributed to the α- 
and β- methylene protons adjacent to the carboxylic group.  
95 
 
 
Figure 4.4: 
1
H NMR spectrum of PG-SA in D2O 
 
From the GPC result, the molecular weight (Mn) was 1742 gmol
-1
. Therefore, by using 
this information, we could calculate the number of protons exist in the broad peak (a). 
The degree of polymerization (DP) was determined by dividing the Mn of PG by the 
molecular weight of glycidol (74.08 gmol
-1
); the value was 24. As glycidol contains five 
protons, these value was multiplied by the DP. Thus, an estimated 120 protons existed in 
(a). These can then be used to calculate the number of protons under peak b. By 
integrating peaks a and b, the number of protons existing in (b) was calculated to be 12. 
Therefore, after synthesising PG with succinic anhydride, there were three carboxylic 
group attached to the surface of the polyglycidol. 
 
This result was supported by 
13
C NMR where the presence of a carboxylic and ester 
group was detected at 177.4 and 174.5 ppm respectively. PG-SA was prepared as an 
intermediate compound before further conjugation with folic acid and poly (ethylene 
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O
O
n 
a 
b 
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glycol) as the spacer. Folic acid was first converted into its active compound as 
described below. 
 
4.2.2  Step 2: Synthesis of folic acid ester (FA-NHS) 
A folic acid ester (FA-NHS)(Scheme 4.1) was produced by reacting folic acid with 1,3-
dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS) in dry DMSO. The 
reaction was stirred continually, light protected and left overnight in a nitrogen 
environment. DCC is a good coupling agent that coupled NHS with carboxylic acid at 
the end of the folic acid. The above reaction produced dicyclohexylurea (DCU) a side 
product of DCC. The DCU was filtered and the filtrate was concentrated using vacuum 
distillation at 40 
o
C. The solution was precipitated using a mixture of cold 
acetone:diethyl ether (30:70) three times and dried overnight in a vacuum. The product 
was a solid yellow powder. The folic acid ester was characterised using 
1
H NMR. 
Figure 4.5 depicts the NMR spectrum of FA-NHS. 
  
Figure 4.5: 
1
H NMR spectrum of FA-NHS in DMSO 
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The spectrum clearly shows the broad carboxylic peak at 11.52 ppm. The presence of a 
folate group was observed at 8.65 ppm (pteridine proton), 8.16 ppm (aliphatic amide 
proton) ,7.67 ppm and 6.66 ppm (aromatic proton).
88
 The NHS peak was depicted at 
2.81 ppm. Further characterisation using 
13
C showed the presence of a carboxylic and 
ester peak at 177.4 and 174.5 ppm respectively.  
Folic acid contains two carboxylate groups γ and α: the former exhibits much higher 
reactivity than the latter.
93
 Therefore, the γ carboxylate position was chosen to couple 
with NHS to form an ester compound. This ester compound was a good leaving group 
when reacted with amine. Consequently, the next step involved the conjugation of the 
activated folic ester with poly (ethylene glycol) bis amine. 
 
4.2.3 Step 3: Synthesis of folate-polyethylene glycol bis amine (Folate-PEG-NH2) 
Folate-PEG-NH2 was prepared by using an N hydroxysuccinimide ester of folic acid 
(FA-NHS) from the previous step (Scheme 4.2). PEG bis amine (Mw = 3400) and FA-
NHS were dissolved separately in dry DMF. After all the reactant was dissolved, the 
solutions were mixed together and diisopropyl ethylamine was added. The mixture was 
allowed to react at room temperature for 24 hours in a nitrogen environment. After the 
reaction was completed, the solvent was reduced using vacuum distillation and finally 
precipitated in diethyl ether and dried in a vacuum. The final product was a pale yellow 
solid. The product was confirmed by 
1
H NMR as shown in Figure 4.6. The presence of 
a folic acid group was detected at 8.67, 7.63 and 6.67 ppm. The PEG peak was detected 
at 3.52 ppm. This result was supported by a 
13
C NMR spectrum at 175.2 ppm and 173.3 
ppm which represents  the carboxylic acid group from folic acid and the amide group.
88 
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Figure 4.6: 
1
H NMR spectrum of PEG-FA in DMSO 
 
In the final step, we conjugated polyethylene glycol with the above targeting moiety to 
produce a good delivering system. This was done through a synthetic route, described 
below. 
 
4.2.4 Step 4: Synthesis of polyglycidol-folate-poly(ethylene glycol) (PG- Folate-
PEG) 
The final product, PG-Folate-PEG, was synthesised using a multi-step reaction. This 
involves a reaction between PG-SA (Scheme 4.3) and Folate-PEG-NH2 (Scheme 4.2). 
PG-SA was dissolved in DMSO, followed by DCC and pyridine. Folate-PEG-NH2 was 
also dissolved in DMSO prior to its addition to the above solution. The mixture was 
allowed to react at room temperature for 24 hours in a nitrogen environment. After the 
reaction was completed, the solvent was reduced to half by vacuum distillation; water 
was added to the sample which was then freeze-dried overnight, yielding a pale yellow 
powder. The powder was characterised using 
1
H NMR, as shown in Figure 4.7. The 
presence of folic acid was detected at 8.70, 7.55 and 6.69 ppm. Recall that in Step 1, the 
-(CH2-CH2-O)n-CH2-CH2-NH2
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1
H NMR for PG was observed in the range of 4.33 – 3.21 ppm and the PEG peak at 3.52 
ppm (Step 3). Therefore, the broad peak was denoted as PEG overlap with the PG peak. 
 
 
Figure 4.7 : 
1
H NMR spectrum of PG-PEG-FA in D2O 
The number of folic acid molecules conjugated to PG can be estimated as follows. From 
Step 1 we calculated there was three carboxylic acids were attached to the PG surface. 
Therefore, a three PEG-Folate would be conjugated to the PG end group. If this had 
happened, it would be expected that the molecule would be much bigger. But, from the 
GPC result, the Mn was only 2151. A qualitative estimation suggested that only one 
might be conjugated to the PG (but one is all we need). 
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Chapter 5: Hydroxyl Terminated PAMAM Dendrimers: Encapsulation 
Using TCPP and Ibuprofen 
 
5.1 Overview 
In the past decade, dendrimers have emerged as promising delivering agents in the 
pharmaceutical world. These polymers have defined compositions, high molecular mass 
and a highly branched structure. These tree-like structures were first introduced by 
Newkome
13
 and Tomalia
14 
in 1985. Dendrimer has  well defined globular three 
dimensional  architechure in which all chains emerged gradually from core towards the 
end of the branching point, low polydispersity, and high surface functionality.
94 
  
With all these attractive properties, dendrimers have become significant candidates as 
nanodrug vehicles due to their nanostructure and chemical versatility.
95 
Compared to 
traditional polymeric drug vehicles, dendrimers have several advantages, such as: 1) 
stable architecture; 2) high density and well-defined surface functionalities, which have 
multifunctional benefits such as targeting, imaging and killing cells, 3) are 
monodispersed polymers, which ensure reproducible pharmacokinetics; 4) can easily 
penetrate through the cell membrane, which enhances cellular uptake of the drug 
complex or conjugation, and 5) have controlled shapes, which make them suitable for 
various medical applications.
100
 
Significantly, dendrimers have proved their ability to enhance the solubility of poorly 
soluble
97-98
 drugs and the bioavailability
99
 of drugs. These is due to hydrophobic species 
inside the dendrimer and the hydrophilic properties at their periphery. The proposed 
mechanism is a hydrophobic interaction between the drug and the hydrophobic interior, 
as well as hydrogen bonding and ionic interaction at the surface of the dendrimer.
100 
Other factors that contribute to the effectiveness of dendrimer as drug delivery vehicles 
are dendrimer generation, pH, core, temperature, polymeric architecture and surface 
functional groups.
94
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5.2 Effect of generation size 
Many efforts have been made to study the effect of dendrimer generation on the 
solubility of hydrophobic drugs. Different generations of both amine and ester 
terminated dendrimers have proved to increase the solubility of nifedipine several fold 
(Figure 5.1).
97
  
 
Figure 5.1: Effect of generation size in solublisation of drugs 
For example, the generation 4 of amine, hydroxyl and ester terminated dendrimers can 
solubilised indomethacin.
102 
Another type of dendrimer with a poly(ethylene glycol) 
core and citric acid as the branching unit also shows that an increase in generation size 
can solubilise hydrophobic molecules such as pyrene, 5-amino salicylic acid, mefenamic 
acid and diclofenac.
103
 Different generations of poly(alkyl aryl ether) dendrimers with a 
phenolic hydroxyl group at the periphery and poly(propylene imine)  can increase the 
solubility of pyrene.
100,101
 Polyamidoamine (PAMAM) dendrimers also showed it can 
solubilised different non-steroidal anti-inflammatory drug (NSAID). The above 
examples prove that generation size and concentration plays an important role in NSAID 
solubilisation.
106 
. 
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5.3  Effect of pH 
Another factor that contributes to drug solubilisation in dendrimers is pH. For instance, 
the protonation of nitrogen whether inside or at the periphery of PAMAM dendrimers is 
highly influenced by pH. The solubility of nifedipine in amine terminated G3 PAMAM 
dendrimer rises linearly with increasing concentration when used at pH 7 and 10 but not 
at pH 4. This was due to the protonation of tertiary amines in these dendrimers, which 
created a polarity environment inside the cavities, hence no increase in solubility. In 
contrast, for ester terminated dendrimers, at pH 4, less nitrogen was protonated; in other 
words, more tertiary amines were available for hydrogen bonding with drug molecules. 
At pH 7 (neutral), both primary and tertiary amines are less influenced for protonation 
compared to pH 4 or 10. As a result, the highest solubilisation effect for nifedipine was 
achieved at pH 7.
101
 
 
5.4  Effect of core, polymer architecture and surface functionalities 
Different cores for synthesising dendrimers can affect their capability to bind 
hydrophobic molecules. The basic idea was to have a dendrimer with a hydrophobic 
core and hydrophilic at the outer shell. For example 3,5-dihydroxy benzyl acohol was 
used as the core to build a dendritic unimolecular micelle. Other researcher used 4,4-
bis(4-hydroxyphenyl) pentanol as the core to construct the dendrimer. Both dendrimers 
were used as solubilisation enhancers for pyrene. The solubility of pyrene using the 
former dendrimer increased to 120 fold whereas the later by 356 fold.
107-108
 A bigger 
core molecule provides larger voids inside the dentritic structure, and these enhance the 
solubility of the guest molecule. 
 
Different polymer architectures provide different solubilisation effects. The 
solubilisation effect of Paclitaxel using PEG 400 was compared with 
poly[oligo(ethylene glycol)methacrylate][poly(OEGMA)], five-arm star-shaped 
polyOEGMA, and polyglycerol dendrimers with G3, G4 and G5 (Figure 5.2).
109
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Figure 5.2: Effect of polymer architecture in solubilising paclitaxel, where (a) is poly(OEGMA), 
(b) is five-arm star-shaped polyOEGMA and (c) are G3, G4 and G5 polyglycerol dendrimers
109
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The results showed that the solubility of all polymers increases tremendously compared 
to PEG 400.
109
 
Researchers have investigated various techniques and modifications to enable drugs to 
be delivered to targeted sites. As reviewed above, another modification suitable for this 
application is to modify the surface functionalities of dendrimers. An ester terminated 
PAMAM dendrimer was modified to a hydroxyl terminated PAMAM dendrimer using 
tris(hydroxymethyl amino methane). This method changed the ester termination into 
three hydroxyl end groups. These can increase the solubility of dendrimers 
significantly.
50
 Other researchers suggest using PEG to enhance solubility and drug 
delivery. The use of different PEG arm length also affects the solubility of drugs.
110-111
 
 
5.5 Dendrimer toxicity 
Dendrimers such as polyamido amine (PAMAM),
94
 as shown in Figure 5.3, with an 
amine group at the periphery can form a stable complex with DNA that can penetrate the 
cell membrane to release DNA inside the cells.
112
 Dendrimers have also been shown to 
be promising drug delivery vehicles for anticancer drugs using specific drugs and 
treatments at specific targeted cancerous sites.
97
 
 
Although dendrimers have shown a tremendous advantage as drug delivery vehicles, 
there are certain aspects that cannot be denied, i.e. the toxicity behaviour caused to the 
cell by the dendrimers. Studies have shown that cationic dendrimers with a NH2 
pheripery are toxic to cells. For example, cationic melamine dendrimers,
113
 
polypropyleneimine (PPI) and poly-L-lysine (PPL)
114
 showe significant toxicity due to 
their surface cationic groups. 
105 
 
 
Figure 5.3: PAMAM dendrimer 
Due to this toxicity issue, it was believed strongly that dendrimers can be modified to 
make them non-toxic and water-soluble, thus making them perfect delivering agents. 
Therefore, this chapter will be discussed on modifications to dendrimers’ surface 
terminal groups. 
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5.6 Aims 
Dendrimers have become promising agents for delivering drugs to specific sites, but 
there are some studies show that while cationic dendrimers can solubilise the drug, they 
can be toxic to the cell.  As a result, it was believed that water soluble dendrimer may be 
the best candidates as drug vehicles for transporting drugs to targeted areas. 
 
In this chapter, a comparison of solubilisation enhancement between water soluble 
hyperbranched polygrycerol with water soluble dendrimer was carried out. This is 
because they have some similarities in the polymer architecture and ability as drug 
delivery systems. For this specific study,  a similar molecular weight of around 4000 Da 
will be used for both macromolecules.  
Initially, PAMAM dendrimers were synthesised from generation 0.5 to generation 2.5. 
Water soluble PAMAM dendrimers were then synthesised using an ester terminated  of 
generation 2.5 PAMAM dendrimers with a tris hydroxymethyl amino methane (TRIS) 
group. The result was the conversion of the ester group into three hydroxyl terminal 
groups at the surface of the dendrimers.  
The synthesised water soluble dendrimers were then compared with water soluble 
hyperbranched polymers using  p-nitrophenol as the core. Hyperbranched polymer was 
synthesised using the anionic polymerisation method using glycidol as the monomer. 
The core to monomer ratio used for this polymerisation was 1:5.  
Both polymers were then encapsulated with model drug and drug, i.e. 
tetracarboxyphenyl porphyrin (TCPP) and ibuprofen respectively. Both drug and model 
drug have some solubility in water. Four different concentrations were used in this 
study; 1.00 x 10
-4 
M, 2.00 x 10
-4 
M, 4.00 x 10
-4 
M and 6.00 x 10
-4 
M.  
Having previously demonstrated  the ability of hyperbranched polymers to solubilise 
both drugs with the above polymer concentrations, a plateau response was revealed. It 
107 
 
was expected that encapsulation with water soluble dendrimers would cause them to 
behave the same as hyperbranched polymers. 
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5.7  Results and discussion 
5.7.1 Synthesis of PAMAM dendrimers 
As previously discussed, PAMAM dendrimer was chosen and the general synthesis of 
PAMAM dendrimers involved two iterative steps, namely 1) 1,4 Michael addition to 
produce ester terminated PAMAM dendrimers and 2) amidation to produce amine 
terminated PAMAM dendrimers or the whole PAMAM generation dendrimers.  
 
1,4 Micheal addition utilises the α-β unsaturated carbonyl compound. The carbonyl 
substituent has an electron-withdrawing effect, which generates a δ positive on the α 
carbon. This α carbon is stabilised by its resonance. Due to this effect, the β carbon 
becomes electropositive,therefore making it prone to nucleophilic attack. In this 
reaction, methyl acrylate acts as α-β unsaturated carbonyl, whereas ethylenediamine is 
the nucleophile. The mechanism of both steps are illustrated in Figure 5.4. 
 
OCH3
O O
OCH3
O
OCH3
NH2
R
O
NH2 OCH3
MeOH
NH OCH3
O
 
Figure 5.4: The 1,4 Michael addition  
 
The second step is amidation. This step consumes the nitrogen lone pair from ethylene 
diamine and behaves as a nucleophile, attracting the positive carbonyl carbon from the 
methoxy group. The mechanism is shown in Figure 5.5 below.  
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Figure 5.5: The amidation reaction  
 
5.7.2 Synthesis of a G0.5 to G2.5 PAMAM dendrimer 
The synthesis of a G0.5 PAMAM dendrimer was achieved by dropwise addition of 
methyl acrylate to ethylene diamine (EDA) dissolved in methanol at 0
o
C. This was 
allowed to return to room temperature and was stirred overnight. Excess ethylene 
diamine was removed under vacuum. The complete removal of these solvent was 
monitored using 
1
H NMR. The product was a viscous honey yellow oil. This is the result 
of the Michael addition involving nucleophilic of ethylene diamine acting as the core. 
The nucleophilic core reacted with four equivalent of methyl acrylates, producing a G0.5 
PAMAM dendrimers of four ester terminal group.  
This ester terminated intermediate was then dissolved in methanol and added dropwise 
to a stirred ethylene diamine for thirty minutes at 0 
o
C. The solution was allowed to 
come to room temperature and was left for five days. Excess EDA was removed using 
an azeotropic mixture of toluene and methanol in a 9:1 ratio. Complete removal of EDA 
was accessed by 
13
C NMR. The product was a slightly viscous honey yellow oil. This 
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was the result of the amidation reaction, producing G1.0 PAMAM dendrimer with four 
amine terminal group. These two steps, the initial Michael addition and amidation, were 
used iteratively to generate higher generations of dendrimers. 
The diamine (G1.0) was dissolved in methanol. Methyl acrylate was then added 
dropwise to the stirred solution for thirty minutes at 0 
o
C. The mixture was brought back 
to room temperature and left overnight. Excess methyl acrylate was removed via a rotary 
evaporator. The product was a G1.5 PAMAM dendrimer possessing eight ester terminal 
groups with more viscous oil. The G2.0 PAMAM dendrimer was synthesised using the 
previous G1.5 dissolved in methanol, and EDA was added dropwise to the solution at 0 
o
C. The reaction was allowed to rise to room temperature and was then allowed to react 
for seven days. Purification was done using an azeotropic mixture of toluene and 
methanol and then the removal of  all EDA was confirmed by 
13
C NMR. The oil 
produced was more viscous, as a result of the dendrimer containing eight amine terminal 
groups. The reaction from G0.5 to a G2.0 PAMAM dendrimer is shown schematically in 
Figure 5.6 below. This  schematic reaction, clearly illustrates that the Michael addition 
(red) and amidation reaction (blue) can be used iteratively to create higher generations of 
dendrimers. 
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Figure 5.6: Synthesis of PAMAM dendrimer G0.5 to G2.0 showing each Michael addition (red) 
and amidation step (blue) 
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To synthesise G2.5 PAMAM dendrimer, the G2.0 PAMAM dendrimer with an amine 
terminated group was dissolved in methanol. To this stirred mixture, methyl acrylate 
was added dropwise at 0 
o
C. The mixture was brought to room temperature and stirred 
overnight. After the reaction was complete, the excess methyl acrylate was removed 
using a rotary evaporator. Finally, further removal of solvent was done using a high 
vacuum pump. A generation 2.5 PAMAM dendrimer with an ester terminal group was 
produced in the form of viscous yellow oil. A schematic diagram of the reaction from 
generation 2.0 to 2.5 PAMAM dendrimer is presented below in Figure 5.7. 
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Figure 5.7: Synthesis of PAMAM dendrimer from G2.0 to G2.5 
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In order to ensure that all the synthesised dendrimers (G0.5 to G2.5) have good 
agreement with the theory discussed above, several characterisation tools were used, 
including 
1
H and 
13
C NMR spectroscopy, IR spectroscopy and mass spectrometry. 
1
H 
NMR is a valuable tool for confirming hydrogen abundance and relative population. 
Figure 5.8 shows the 
1
H NMR for G0.5 with a strong methoxy peak (a) observed at 3.68 
ppm. This is the characteristic peak of an ester terminated half generation dendrimer. 
Two triplets at 2.76 ppm (b) and 2.49 ppm (c) were attributed to the existence of newly 
formed CH2 groups and a singlet found at 2.54 ppm (d) indicated the proton from the 
core (ethylene diamine). 
 
Figure 5.8: 
1
H NMR spectrum for G0.5 PAMAM dendrimer in MeOH 
The spectra of higher dendrimer generations are more difficult to interpret. This is due to 
the presence of too many protons. As a result, there were large regions of overlap and 
broadened triplets and multiplets. These are shown in Figure 5.9.  On the G2.5 
PAMAM dendrimer spectrum, a very strong singlet peak (a) associated with methoxy 
was observed at 3.66 ppm. There were multiplet at 3.37 ppm (b) and two multiplets 
a 
b 
d 
c 
N N
H3CO
o
H3CO
o
OCH3
o
OCH3
o  
a 
b 
d 
c 
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ranging from 2.93 to 2.33 ppm (c) indicating the existence of CH2 groups in the 
dendrimer architecture.  
 
Figure 5.9: 
1
H NMR spectrum of a generation 2.5 PAMAM dendrimer 
Another characterisation used to confirm the above dendrimer was mass spectroscopy. 
This showed that the molecular ion peak was almost the same, with the exact molecular 
weight predetermined from the ideal structure shown in Table 5.1. Another 
interpretation tool used to approve these structure was IR spectroscopy. The spectra 
showed a significant ester peak at 1730 cm
-1
 for ester terminated PAMAM dendrimers. 
For  amine terminated PAMAM dendrimers,  an amide peak was observed at around 
3200 cm
-1
 and an amide carbonyl peak at 1640 cm
-1
. Finally, after all the above 
characterisation was completed, we were confident in the synthetic procedure used to 
synthesise the generation 2.5 PAMAM dendrime 
 
 
a 
  b 
c 
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Table 5.1: The molecular weight for G0.5 to G2.5 PAMAM dendrimers 
PAMAM 
generation 
End group Molecular 
formula 
MH
+
 
peak 
Expected Mw 
0.5 CO2Me (4) C18H32 N2O8 405 404 
1.0 NH2(4) C22H48N10O4 517 516 
1.5 CO2Me(8) C54H88N10O20 1206 1196 
2.0 NH2(8) C62H128N26O12 1468 1428 
2.5 CO2Me(16) C124H224N26O44 4130 2805 
 
5.7.3 Purification of the PAMAM dendrimer 
The half generation PAMAM dendrimer underwent  Michael addition reaction and the 
excess methyl acrylate used was easily removed because of the high volatility of the 
compound. The removal was easily done using rotary evaporator. However, for an 
amidation step, the ethylenediamine (EDA) is not easily removed and therefore affects 
the following synthetic procedure. Incomplete removal of EDA can behave as a new 
initiator core, which will react to form undesired by-products. This abnormality is 
illustrated in Figure 5.10 below: 
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Figure 5.10: Incomplete removal of EDA and their by-products 
 
The by-products were G1.5 and G0.5, which were generated together. If these occurred, 
these two different generation PAMAM dendrimers were extremely difficult to remove 
due to their structural and physical similarity to the desired dendrimer. Consequently, 
these would lead to substantial broadening of the molecular weight distribution. 
The efficient way to eradicate EDA was by washing repeatedly with an azeotropic 
mixture. This mixture was a combination of toluene and methanol with a 9:1 ratio. The 
G1.0 PAMAM dendrimer was added with the above solution and placed in a rotary 
evaporator. How this azeotropic solution works is explained below. The G1.0 PAMAM 
dendrimer possesses four amine terminated surface groups. EDA forms hydrogen bond, 
which is strongly bound to the amine terminal group. In order to prevent this occurance, 
something must be incorporated into the solution to bind with the hydrogen bonding 
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sites. Methanol is a good competitor for these sites, but has the limitation of a low 
boiling point. Upon evaporation, the concentration decreases, meaning it is removed 
from the binding sites, which EDA will then occupy. By using an azeotropic solution, 
methanol can be a good competitor, as toluene will increased the azeotropic solution 
boiling point and facilitate the removal of EDA. 
The complete removal of methyl acrylate was confirmed using 
1
H NMR. Methyl acylate 
vinyl groups usually appeared at around 5-6 ppm. However, for EDA, 
13
C NMR was 
used, and the EDA peak was easily visualised at 43.6 ppm. 
Consequently, the following discussion will focus on synthesising water soluble 
PAMAM dendrimers which contained 48 hydroxyl groups at the periphery. 
 
5.7.4 Synthesis of PAMAM dendrimer with 48 hydroxyl groups 
A further reaction using the G2.5 PAMAM dendrimer to generate a hydroxyl terminated 
dendrimer was performed. Tris(hydroxymethyl) aminomethane (TRIS) and anhydrous 
potassium carbonate were dissolved in dry DMSO. To this suspension, PAMAM 
generation 2.5 dissolved in dry DMSO was added. The mixture was allowed to react for 
72 hours at 50 
o
C under nitrogen conditions. The solution was then filtered and the 
solvent removed using vacuum distillation at 40
o
C. Finally, a small amount of water was 
added, followed by acetone to precipitate the product. A pale yellow viscous oil was 
collected. The  reaction mechanism indicating the conversion of PAMAM generation 2.5 
to a hydroxyl terminated dendrimer is shown in Figure 5.11. 
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Figure 5.11: Synthesis of a generation 2.5 PAMAM dendrimer into a hydroxyl terminated 
PAMAM dendrimer 
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To prove the above compound was successfully synthesised, the product was 
characterised using 
1
H NMR, 
13
C NMR and mass spectroscopy. The proton peaks 
associated with methylene protons adjacent to the terminal hydroxyl groups were seen at 
3.64 ppm. A series of broad multiplets was observed in conjunction with the CH2 peaks 
in the dendrimer architecture. The carbonyl peaks at 174.4 ppm and 175.4 ppm indicated 
the interior amide and exterior amide respectively.
50
 The methyl group was completely 
removed from the 
13
C NMR spectra. Mass spectrometry revealed a molecular ion of 
4130. Further characterisation using IR showed an OH broad band at 3303 cm
-1
 and 
amide carbonyl at 1657 cm
-1
. As expected, the hydroxyl terminated PAMAM dendrimer 
was soluble in water. 
 
5.7.5 Encapsulation of hydrophobic molecules with water soluble PAMAM 
dendrimer 
 
In this study, two hydrophobic molecule were used, namely ibuprofen and 
tetracarboxyphenyl porphyrin (Figure 5.12). The properties of both molecules have 
been extensively discussed in Chapter 3.  
H3C
CH3
CH3
OH
O
H NH NH
H
N
O
OH
OHHO
OH
O
O O  
Figure 5.12: Molecules used in complex forming 
Encapsulation was carried using four different concentrations, i.e. 1.00 x 10
-4 
M, 2.00 x 
10
-4 
M, 4.00 x 10
-4 
M and 6.00 x 10
-4 
M,  of PAMAM dendrimers with 48 OH terminal 
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groups. Dendrimers and guest molecules were dissolved separately in methanol and then 
mixed together. The methanol was then removed using a rotary evaporator giving a 
dendrimer/guest molecules co-precipitate. Finally TRIS buffer (pH 7.4 with 0.1M) was 
added. All insoluble substances were filtered prior to UV measurement. 
 
5.7.5.1. Encapsulation of ibuprofen with water soluble PAMAM dendrimers 
The first drug used was ibuprofen with molecular weight of 206.28 g mol
-1
 and its  
characteristic peak detected at λmax = 222 nm. This drug has some solubility in water 
(less than 1 mg/ml~less than 4.80 x 10
-3
 M). After encapsulation, the peak observed was 
too strong and therefore it was diluted 50 fold. The initial concentration was calculated 
by dividing the absorbance by the extinction coefficient (ε) of ibuprofen. The extinction 
coefficient value was obtained graphically from a Beer Lambert plot at 8387.5 M
-1 
cm
-1
. 
It was then multiplied by 50 to get the concentration. 
 
In order to know exactly how much ibuprofen was encapsulated inside the dendrimer, 
ibuprofen was freshly dissolved in water and filtered. The solution was measured using 
UV-Vis spectrophotometer and the value obtained was 2.68 x 10
-4
 M. These amount was 
then substracted from the initial results. The results are tabulated in Table 5.2 below. 
Table 5.2: Ibuprofen concentration in solution and encapsulated ibuprofen with dendrimer 
 
Dendrimer concentration 
(x 10
-4 
M) 
 [Ibuprofen] 
(x 10
-4 
M) 
[Ibuprofen] encapsulated 
inside dendrimer* 
(x 10
-4 
M) 
Without polymer 2.68 0.00 
1.00 5.78 3.10 
2.00 7.18 4.50 
4.00 8.54 5.86 
6.00 9.91 7.23 
* concentrataion of encapsulated ibuprofen after deduction of freshly soluble material 2.68 x 10
-
4
 M 
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The effect of dendrimer concentration on the solubility of ibuprofen in the presence of 
water soluble PAMAM dendrimers is shown in Figure 5.13. The solubility of ibuprofen 
in water was 2.68 x 10
-4
 M. It was observed that the solubility of ibuprofen was 
significantly improved by the PAMAM dendrimer. The solubility increased up to the 
highest concentration of dendrimer used, which was 6.00 x 10
-4
 M. The increase in 
solubility of ibuprofen was presumably attributed to the internal cavities inside the water 
soluble PAMAM dendrimer interacting with the ibuprofen. Furthermore, there were 
tertiary amines inside the cavities which could interact with ibuprofen by hydrogen bond 
formation.
94
 
 
Figure 5.13: Increased ibuprofen solubility with increased concentration of water soluble 
dendrimer 
 
If considered carefully, the graph increase was not linear. For example, for polymer 
concentration of 1.00 x 10
-4 
M, the solubility was 3.10 x 10
-4 
M, we should predicted that 
for polymer concentration of 2.00 x 10
-4 
M, the ibuprofen solubility should be around 
6.00 x 10
-4 
M, but it not happened. When we looked at polymer concentration of 4.00 x 
10
-4 
M the ibuprofen concentration should be around 12.00 x 10
-4 
M, but it only 
increased up to 5.86 x 10
-4 
M. The ideal situation is demonstrated in the cartoon in 
Figure 5.14 below. 
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The figure below showed the ideal situation, where, when one polymer can encapsulated 
3 guest molecules, therefore for four polymers, they can encapsulated twelve guest 
molecules. 
                                                   
 
 
 
      
 three guest molecules     six guest molecules         twelve guest molecules 
Figure 5.14:  Expected model of encapsulated ibuprofen within dendrimers 
However, the graph in Figure 5.13 showed that the ibuprofen concentration was initially 
increased and plateaued at dendrimer concentration of 6.00 x 10
-4
 M. At this stage, it 
was decided to investigate the possible aggregation  behaviour of the dendrimers at 
higher concentration. It was reported that amine terminated dendrimers aggregate around 
10
-3
-10
-6
 M and the OH terminated dendrimers aggregate around 10
-4
-10
-6
 M.
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The 
onset of aggregation, known as critical aggregation or micelle concentration (CMC), is 
often accompanied by a direct change in solution properties. It was almost certain 
aggregation has occurred in the dendrimers. On examining the ibuprofen concentration 
versus dendrimer concentration plot, it was clearly shown a prominent break in linearity 
observed at 1.5 x 10
-4
 M. This is the beginning of aggregation in dendrimers.
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Loading per mole ibuprofen inside dendrimer was determined by dividing the 
concentration of ibuprofen by the concentration of dendrimer. For dendrimer 
concentration of 1.00 x 10
-4 
M, loading per mole ibuprofen was three. For the next 
discussion, a bigger molecule was used for encapsulation study, which was TCPP. 
 
5.7.5.2  Encapsulation of TCPP with water soluble PAMAM dendrimers 
The second drug molecule used was tetracarboxyphenyl porphyrin (TCPP). This 
molecule is bigger than the ibuprofen molecule. We used the same  encapsulation 
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method as before with four different dendrimer concentrations. The absorbance of the 
solution was too strong, thus it was diluted 100 fold. The concentration was calculated 
by dividing the absorbance by extinction coefficient (ε) value of TCPP which was 3.30 x 
10
5 
M
-1
 cm
-1
. The value was then multiplied by 100. In order to know the value of TCPP 
encapsulated in the dendrimer, the value was deducted from the value of TCPP 
dissolved in water. This experiment was done by dissolving excess TCPP in water, and 
any undissolved TCPP was filtered off. The solution was then assessed by UV-Vis 
spectrophotometer  with a value of 0.72 x 10
-4
 M. This value was then deducted with the 
concentration of TCPP in solution. From these results, we also can calculate loading per 
mole TCPP inside the dendrimer. These value was obtained by dividing the TCPP 
concentration by the dendrimer concentration. All datas are tabulated in Table 5.3 
below. 
Table 5.3: TCPP concentration in solution and encapsulated  TCPP in dendrimer 
 
[Dendrimer]  
(x 10
-4 
M) 
[TCPP] 
(x 10
-4 
M) 
[TCPP] encapsulated 
inside dendrimer* 
(x 10
-4 
M) 
Without polymer 0.72 0.00 
1.0 1.85 1.13 
2.0 2.42 1.70 
4.0 3.09 2.37 
6.0 4.40 3.68 
* concentrataion of encapsulated TCPP after deduction with 0.72 x 10
-4
 M 
 
From the above results, the effect of different concentrations of dendrimers on the 
solubility of TCPP can be clearly seen. It was observed that the solubility of TCPP 
increased linearly until polymer concentration of 2.00 x 10
-4 
M and plateaued at the 
highest dendrimer concentration of 6.00 x 10
-4 
M, as shown in Figure 5.15. 
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Figure 5.15: Increased solubility of TCPP with increased concentration of water soluble 
dendrimers 
 
It was postulated that the proposed mechanism was due to the hydrophobic bonding of 
drug molecules inside the cavity of the dendrimers. Another factors that  presumably 
contributed to the increased solubility was the internal amide inside the cavities, which 
may interact with TCPP to form hydrogen bonds.
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As previously discussed, the TCPP  
solubility increased after encapsulation with dendrimers, however, the increment was 
not linear. It was clearly demonstrated that the dendrimers aggregated at higher 
concentration. From Figure 5.15 the dendrimer started aggregating at dendrimer 
concentration of 1.5 x 10
-4
 M. Loading per mole TCPP for dendrimer concentration of 
1.00 x 10
-4
 M was one. This might because the TCPP molecule was big and only one 
molecule could solubilised inside the dendrimer hydrophobic voids. 
From the encapsulation studies of both molecules, it was clearly observed that the 
solubility increased with an increased in dendrimer concentration. The following section 
will compare the solubility behaviour between water soluble PAMAM dendrimers and 
water soluble hyperbranched polymers. 
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5.7.6 Comparison of the effect of PAMAM dendrimers and hyperbranched 
polymers on the solubility enhancement of ibuprofen and TCPP 
 
This section specifically compares the solubilisation behaviour of hyperbranched 
polymers and OH terminated dendrimers. Both macromolecules are soluble in water. 
Comparisons were made using the same drug molecules, concentrations, method and 
similar molecular weight. We envisaged that the 48 OH terminal group was suitable in 
this study because the molecule was not very big and was less expensive than other 
bigger dendrimer molecules. The results for both complex formations are shown in 
Figure 5.16 and 5.17: 
 
Figure 5.16: Encapsulation of ibuprofen using water soluble hyperbranched polymers and 
dendrimers 
 
 
The above graph shows the encapsulation of ibuprofen using water soluble 
hyperbranched polymers and dendrimers. Ibuprofen has some solubility in water at 2.63 
x 10
-4
 M. After encapsulation with hyperbranched polymer at a  concentration of 1.00 x 
10
-4
 M, the solubility increased to 5.30 x 10
-4
 M whereas with the dendrimer, the 
solubility increased to 3.01 x 10
-4
 M. Both polymers showed increased solubility after 
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encapsulation. The graph trend line, both polymers showed a linear responds at polymer 
concentration of 2.00 x 10
-4
 M and became plateaued at polymer concentration of 6.00 x 
10
-4
 M.  
 
Figure 5.17: Encapsulation of TCPP using both polymers 
Figure 5.17 shows the encapsulation studies of TCPP encapsulated with both polymers. 
For both polymers, the solubility rose linearly at polymer concentration of 2.00 x 10
-4
 M 
and plateaued at polymer concentration of 6.00 x 10
-4
 M.  The above graphs also showed 
that the solubilisation of the hyperbranched polymers were better than the dendrimers. It 
was postulated that the plateaued trend line of the polymers might be due to the 
aggregation of polymers at higher concentration. 
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Chapter 6: Conclusion 
Most new drugs developed by the pharmaceutical industry are not beneficial to the 
patient because of their poor solubility. There is an urgent need to develop a delivery 
agent which will enhance the solubility of drugs. Over the past decades, many drug 
carriers have been developed including linear polymers, block copolymers and 
dendrimers. In this study, water soluble hyperbranched polymers were chosen because 
they can be prepared using one-pot synthesis and are very cost-effective. 
 
Water soluble hyperbranched polymers with a p-nitrophenol core and glycidol monomer 
were synthesised using anionic ring-opening polymerisation. These polymers have a 
hydrophobic interior and are hydrophilic at the surface. Five different molecular weights 
were prepared using different core to monomer ratios which were 4000 Da, 8500 Da, 
12500 Da, 27500 Da and 50000 Da. For each molecular weight, four different 
concentrations which were 1.00 x 10
-4
 M, 2.00 x 10
-4
 M, 4.00 x 10
-4
 M and 6.00 x 10
-4
 
M were prepared.  
 
These water soluble hyperbranched polymers were used to solubilise several 
hydrophobic molecules. The molecules used were naphthalene, tetracarboxyphenyl 
porphyrin, ibuprofen and anti-prion drug. The results clearly demonstrated that 
hyperbranched polymers are capable of solubilising hydrophobic molecules. For a lower 
concentration of polymers, solubility increased linearly with the concentration of 
hydrophobic molecules. However, at a higher polymer concentration, the concentration 
of hydrophobic molecules plateaued. This was due to the aggregation of the polymers. 
When this occurred, only a small number of guest molecules were able to diffuse inside 
the cavity of the hyperbranched polymer. It was concluded that the optimum 
concentration of model drugs (naphthalene and TCPP) and drug (ibuprofen) used  was in 
the range of 2.00  x 10
-4
 M and 4.00 x 10
-4
 M. The highest polymer molecular weight 
which give optimum effect of solubilisation is 12500 Da. The final hydrophobic 
molecule used was anti-prion drug which was insoluble in water. The results showed 
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that the hyperbranched polymers increased the solubility of the drug. A cytotoxicity test 
showed that the hyperbranched polymers were not toxic to the SMB cell. 
 
In order to make the hyperbranched polymers suitable for targeting specific sites, we 
conjugated folic acid at the surface of the hyperbranched polymers through PEG as the 
spacer. After a lot of discussion and experimentation, several steps were developed to 
produce hyperbranched polymers conjugated with folic acid through poly(ethylene) 
glycol as the spacer: 
 Step 1 – synthesis of polyglicidol succinic anhydride (PG-SA) 
 Step 2 – synthesis of folic acid ester (FA-NHS) 
 Step 3 – synthesis of folate-poly(ethylene glycol) bis amine (Folate-PEG-NH2) 
 Step 4 – synthesis of polyglicidol-folate-poly(ethylene glycol) (PG-Folate-PEG) 
 
The first step was to convert the OH surface of the PG functional group to a carboxylate 
group (PG-SA). The second step was preparation of the folic acid ester (FA-NHS) 
followed by conjugation of the PEG spacer (Folate-PEG). The final step was 
conjugation of PG-SA with Folate-PEG to produce PG-PEG-Folate. The macromolecule 
is suitable for targeted cancer treatment.  
 
Dendrimers are unique synthetic macromolecules that have attracted much attention as 
drug delivery systems. We therefore made a comparison between dendrimers and 
hyperbranched polymers as solubilising enhancers for hydrophobic molecules. Different 
generations (G0.5 to G2.5) of PAMAM dendrimers were synthesised using two iterative 
steps, i.e. Michael addition and amidation. For dendrimers that underwent the Michael 
addition reaction, ester-terminated PAMAM dendrimers were produced. The amidation 
reaction produced amine-terminated PAMAM dendrimers.  
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In order to make these dendrimers suitable for drug delivery, the G2.5 amine-terminated 
PAMAM dendrimers were converted to hydroxyl-terminated PAMAM dendrimers. This 
was achieved by introducing TRIS to the dendrimers, and each ester terminal group was 
converted to three hydroxyl groups at the surface of the PAMAM dendrimers. 
 
These water-soluble PAMAM dendrimers then underwent an encapsulation study with 
ibuprofen and TCPP. The results clearly demonstrated that the dendrimers easily 
increased the solubility of both molecules. The dendrimer shown to aggregate at the 
concentration of 1.5 x 10
-4
 M. We then compared the solubility enhancement behaviour 
of hyperbranched polymers and dendrimers. For this investigation, we used a similar 
molecular weight of 4000 Da for both polymers. The result showed for both polymers, 
the drug molecule concentration increased and plateaued at a higher polymer 
concentration. From the result, it was demonstrated that hyperbranched polymers have 
more solubilisation effect than dendrimers for both ibuprofen and tetracarboxyphenyl 
prophyrin. 
 
For future works, further investigation should be carried out including drug release 
study, toxicity test, particle size analysis and degradation studies. 
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Chapter 7: Experimental  
7.1 General Description of Chemicals and Instrumentation 
 
Solvents and reagents 
All chemicals and reagents were obtained from commercial supplier (Sigma Aldrich, 
BDH Chemicals) and freshly used.  
 
Nuclear magnetic resonance spectroscopy (NMR) 
All sample were characterized via 
1
H and 
13
C NMR which was recorded at 250 MHz 
and 63 MHz on a Bruker AC  and were referenced internally to residual proton signals 
of the deuterated solvent. The spectra were analysed using Bruker 1D Win-NMR, 
version 6.2.0.0. 
 
Fourier transform infrared dpectroscopy (FTIR) 
FTIR spectroscopy was performed using Perkin Elmer Spectrum RX FT-IR System in 
the range of 700 to 4000 cm
-1
.  
 
Gel permeation column (GPC) 
Aqueous GPC data was performed using  Millipore Waters Lambda-Max 481 LC 
spectrometer with a LMW/HMW column. The eluent used was NaNO3/NaH2PO4 at pH 
7. Calibration was done using polyethylene glycol-polyethylene oxide standards (Mn 
220-1, 1,000,000 Da). The molecular weights were reported relative to these standard. 
Raw data obtained was further analysed using cirrus GPC online software. 
 
UV-vis spectroscopy 
The absorbance was recorded using Specord S 600 machine and analysed using 
WINASPECT spectroanalytical software. 
 
Mass spectroscopy 
Two types of equipment used to determined the mass, depending on the molecular 
weight of sample. Lower molecular weight (2-800 Da), Electrospray Ion Mass 
Spectrometry (ESI) was used and recorded using Micromass Prospec spectrometer. 
Molecular weight of more than 800 Da, Matrix Assisted Laser Desorption Ionistion 
Time of flight (MALDI-TOF) spectrometry was used. The experiment was done using 
dithranol or dihydroxy benzoic acid matrices on Bruker III mass spectrometer.  
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7.2 Synthesis of hyperbranched polymers 
 
General synthesis of hyperbranched polymers 
All chemical used were purchased from Sigma-Aldrich UK and used as received. 
Polymerization was carried out in three neck round bottom flask equipped with 
mechanical stirrer and fitted with a condenser under nitrogen atmosphere. Para-
nitropehenol was dissolved in certain amount of diethylene glycol dimethyl ether at 50 
o
C. After all core was dissolved, the temperature was increased to 90 
o
C and NaH was 
added. Various amount of glycidol was added using mechanical pump for 12 hours and 
then left for further 5 hours. Then, the reaction was allowed to cool at room temperature 
and the solvent was poured off. The product which was a brown polymer, was dissolved 
in methanol and then precipitated in 400 ml of acetone. The mixture was left for an hour 
and the solvent was disposed. This method was repeat twice. 
 
Synthesis of polyglycerol using 1:5 ratio 
The general scheme above was used to synthesise the polymer. p-nitrophenol (200.00 
mg, 1.44 mmol), diethylene glycol dimethyl ether (20 ml), sodium hydride (11.52 mg, 
0.48 mmol) and glycidol (530.00 mg, 7.19 mmol). The product (200.25 mg, 31% by 
mass) was brownish viscous polymer  and dried in vacuum oven overnight.  
1
H NMR (D2O, 250 MHz) δH = 3.35-4.56 (b, polymer backbone), 2.16 (s, OH), 
13
C 
NMR (D2O  250 MHz) δH = 62.4, 70.8, 78.3; FTIR (cm
-1
) 3362 (OH), 2891 (CH2, CH); 
GPC (Mn) 4000, (Mw) 7200, PD = 1.8 
 
Synthesis of polyglycidol using a 1:10 ratio 
The general scheme above was used to synthesise the polymer. The reaction used para-
nitrophenol (210.00 mg, 1.44 mmol), diethylene glycol dimethyl ether (20 ml), sodium 
hydride (11.52 mg, 7.00 mmol), glycidol (1.18 g, 15.10 mmol).  The product (400.20 
mg, 30 % by mass) was brownish viscous polymer  and dried in vacuum oven overnight. 
1
H NMR (D2O, 250 MHz) δH = 3.3-4.0 (b, polymer backbone), 2.22 (s, OH), 
13
C NMR 
(D2O,  250 MHz) δH = 62.3, 70.9, 78.6; FTIR (cm
-1
) 3361 (OH), 2870 (CH2, CH); GPC 
(Mn) 8500, (Mw) 17000, PD = 2.0 
 
Synthesis of polyglycidol using a 1:25 ratio 
The general scheme above was used to synthesise the polymer. The reaction used para-
nitrophenol (200.00 mg, 1.44 mmol), diethylene glycol dimethyl ether (20 ml), sodium 
hydride (11.52 mg, 0.48 mmol), glycidol (2.66 g, 35.97 mmol).  The product (400.35 
mg, 15% by mass) was brownish viscous polymer  and dried in vacuum oven overnight. 
1
H NMR (D2O, 250 MHz) δH = 3.39-4.28 (b, polymer backbone), 2.19 (s, OH), 
13
C 
NMR (D2O,  250 MHz) δH = 63.2, 71.2, 79.2; FTIR (cm
-1
) 3366 (OH), 2868 (CH2, CH); 
GPC (Mn) 12500, (Mw) 28750, PD = 2.3 
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Synthesis of polyglycidol using a 1:50 ratio 
The general scheme above was used to synthesise the polymer. The reaction used para-
nitrophenol (200.00 mg, 1.44 mmol), diethylene glycol dimethyl ether (20 ml), sodium 
hydride (11.52 mg, 7 mmol), glycidol (5.52 g, 74.62 mmol).  The product (500.36 mg, 9 
% by mass) was brownish viscous polymer  and dried in vacuum oven overnight. 
1
H NMR (D2O, 250MHz) δH = 3.32-4.15 (b, polymer backbone), 2.19 (s, OH), 
13
C NMR 
(D2O, 250MHz) δH = 62.3, 70.6, 78.9; FTIR (cm
-1
) 3361 (OH), 2860 (CH2, CH); GPC 
(Mn) 27500, (Mw) 96250, PD = 3.5 
 
 
Synthesis of polyglycidol using a 1:100 ratio 
The general scheme above was used to synthesise the polymer. The reaction used para-
nitrophenol (210.00 mg, 1.44 mmol), diethylene glycol dimethyl ether (20 ml), sodium 
hydride (11.52 mg, 7 mmol), glycidol (11.18 g, 151.08 mmol). The product (500.36 mg, 
4 % by mass) was brownish viscous polymer  and dried in vacuum oven overnight. 
1
H NMR (D2O, 250 MHz) δH = 3.33-4.23 (b, polymer backbone), 2.15 (s, OH), 
13
C 
NMR (D2O,  250 MHz) δH = 62.5, 71.3, 78.5; FTIR (cm
-1
) 3365 (OH), 2860 (CH2, CH); 
GPC (Mn) 50000 (Mw) 300000, PD = 6.0 
 
 
Synthesis of tetracarboxyphenyl porphyrin (TCPP) 
The synthesis was done by mixing propionic acid (250 ml) and 4-carboxybenzaldehyde 
(8.25 g, 54.95 mmol) in a three neck round bottom flask fitted with a condenser. The 
reaction mixture was heated until reflux and pyrrole (3.70 ml, 55.14 mmol) was added to 
the reaction via syringe. Refluxing was continued approximately for 1 hour with stirring. 
The product was separated from the reaction by hot filtration and washed with 
dichloromethane. TCPP obtained was washed with cold methanol and the solid purple 
filtrate was collected and dried under vacuum. Yield : 4.00 g; 2%) 
1
H NMR (DMSO, 
250 MHz), δH 13.32 (s, 4H, COOH), 8.86 (s, 8H, pyrrolic-β-CH), 8.23 (q, 16H, phenylic 
CH), -2.95 (s, 2H, NH), 
13
C NMR (DMSO, 250 MHz)  δ 167.4, 127.9. 40.1, 39.8, 39.4, 
39.1, 38.8, 38.5.,FTIR υmax (cm
-1
): 2626, 2725, 1683, 1602, 1463, 1377, UV/vis (MeOH) 
λmax : 418.0, 515.0, 547.5, MH
+
 (ESI-MS) = 791 (calculated 791 gmol
-1
), C48H30N4O8, 
Elemental analysis, C: 67.69%, H: 4.27%, N: 5.52%, O: 22.52% (calculated C: 72.9%, 
H: 3.82%, N: 7.09%, O:16.19%) 
 
Beer-Lambert experiment for naphthalene, ibuprofen and tetracarboxyphenyl 
porphyrin 
10.00 mg of each compound was dissolved in methanol (1 L). The absorbance of all 
samples were measured using UV spectrophotometer at their characteristic wavelength ( 
naphthalene: 219 nm, ibuprofen: 222 nm, TCPP: 415 nm) with methanol as reference. 
Further dilution was made up using a 100 ml volumetric flask. 10 ml of stock solution 
was taken out and  the flask was filled to the mark with methanol and swirled to mix. 
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These steps were repeated a few times until a graph indicating absorbance versus 
concentration could be plotted. 
 
Beer-Lambert of anti-prion drug 
The above experiment was conducted by dissolving 10.00 mg of the drug  and dissolved 
in 1L methanol. The absorbance was recorded at 325 nm was measured using UV-Vis 
spectrophotometer with methanol as reference. Further dilutions were conducted using 
100 ml volumetric flask. The steps were repeated a few times until a graph indicating 
absorbance versus concentration could be plotted. 
 
7.2.1  General procedures for encapsulation studies 
Preparation of four different concentration from different molecular weights 
Four different concentration ie 1.00, 2.00, 4.00 and 6.00 (x 10
-4
) M of hyperbranched 
polymers were prepared.  
 
Molecular weight of 4000 
4.00 mg, 8.00 mg, 16.00 mg and 24.00 mg of the polymer was dissolved in 10 ml of 
methanol to make of the above concentrations. 
 
Molecular weight of 8500 
8.50 mg, 17.00 mg, 34.00 mg and 60.00 mg of the polymer was dissolved in 10 ml of 
methanol to make the above concentrations. 
 
Molecular weight of 12500 
12.50 mg, 24.00 mg, 50.00 mg and 75.00 mg of the polymer was dissolved in 10 ml of 
methanol to make the above concentrations. 
 
Molecular weight of 27500 
27.50 mg, 55.00 mg, 110.00 mg and 165.00 mg of the polymer was dissolved in 10 ml 
of methanol to make the above concentrations. 
 
Molecular weight of 50000 
50.00 mg, 100.00 mg, 200.00 mg and 300.00 mg of the polymer was dissolved in 10 ml 
of methanol to make the above concentrations. 
 
Preparation of 0.01M buffer solution 
12.1 g of tris(hydroxymethyl) aminomethane was dissolved in 1 L of deionised water to 
make the concentration of 0.1 M  
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Encapsulation of naphthalene with hyperbranched polymers 
100.00 mg  of naphthalene, was dissolved in 10 ml of methanol in a vial. The solution 
was added to each polymer solution prepared. The solution was physically mixed for 5 
minutes and the solvent was removed under vacuo. Then, 10 ml of buffer solution was 
added to the sample. The sample was repeated at least two times. The absorbance of all 
samples were recorded at their characteristic wavelengths. 
 
Encapsulation of ibuprofen with hyperbranched polymers 
100.00 mg  of ibuprofen, was dissolved in 10 ml of methanol in a vial. The solution was 
added to each polymer solution prepared. The solution was physically mixed for 5 
minutes and the solvent was removed under vacuo. Then, 10 ml of buffer solution was 
added to the sample. The sample was repeated at least two times. The absorbance of all 
samples were recorded at their characteristic wavelengths. 
 
Encapsulation of TCPP with hyperbranched polymers 
100.00 mg  of TCPP, was dissolved in 10 ml of methanol in a vial. The solution was 
added to each polymer solution prepared. The solution was physically mixed and the 
solvent was removed under vacuo. Then, 10 ml of buffer solution was added to the 
sample. The sample was repeated at least two times. The absorbance of all samples were 
recorded at their characteristic wavelengths. 
 
Encapsulation of anti-prion drug with hyperbranched polymers 
10.00 mg of hyperbranched polymer and 5.00 mg of anti-prion drug were dissolved in 
10 ml of methanol in different vial. Both solutions were added together and physically 
mixed for 5 minutes and the solvent was removed under vacuo. Then, 10 ml of distilled 
water was added to the sample. The absorbance was recorded at its characteristic 
wavelength. 
 
7.2.2 Cytotoxicity Studies 
 
Cytotoxicity evaluation for hyperbranched polymer and encapsulated anti-prion 
drug with hyperbranched polymer 
 
Cytotoxicity study of hyperbranched polymer with four different molecular weight ie 
4000 Da, 8500 Da, 12500 Da and 50000 Da was conducted against SMB cell line using 
MTT assay. The SMB cells were grown in medium 199 Eagle salts supplemented with 
10% newborn calf serum, 5% foetal calf serum and 5% penicillin-streptomysin at 
10ml/L and allowed to grow for 24 hours at 37
o
C under 5% CO2 in air and 95% 
humidity. Different concentrations of hyperbranched polymers ie 100 µM, 500 µM and 
1000 µM were added to the cell and incubated for 5 days at 37
o
C. For the measurement 
of cell viability, 10 µl of 5 mg/ml of MTT solution was added into 96 well plates for 2 
hours at 37 
o
C . After treatment, the medium was removed and 30 µL of acidic 
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isopropanol was added to each well to extract the formazan dye out from the cell wall, 
which produced a purple colour. The absorbance of the dye was measured at its 
characteristic wavelength at 570 nm with reference at 690 nm. 
 
7.3 Functionalisation of hyperbranched polymer with folic acid and PEG spacer 
Synthesis of polyglycidol-succinic acid (PG-SA) 
To a two neck round bottom flask was added PG (500.00 mg, 0.12 mmol) and dissolved 
in dry methanol (75 ml). After all PG was dissolved, succinic anhydride (1.58 g, 15.78 
mmol) was added and the flask was evacuated and filled with nitrogen gas. The mixture 
was refluxed for 48 hours at 125 
o
C, using a drying tube. Then, the solution was 
removed in half and the remained, was precipitated in acetone (400 ml). This step was 
repeated three times  and the precipitated was filtered and dried  in vacuum oven 
overnight. The product was viscous dark yellow solid. Yield=1.00 g, 48%. 
1
H NMR ( 
D2O, 250 Mhz): δH = 8.25 (s, 2H, nitrophenol), 7.25 (s, 2H, nitrophenol), 4.33 – 3.21 (b, 
polymer backbone), 2.54 (s, 16H, succinic acid, CH2). 
13
C NMR (D2O, 250 Mhz): δc = 
177.4, 174.5, 79.4, 68.8, 60.7, 29.0, GPC (aqueous) : Mn = 1714 
 
Synthesis of folic acid ester (FA-NHS) 
Folic acid (1.00 g, 2.26 mmol) was dissolved in 10 ml of dry DMSO and was activated 
by 1,3-dicyclohexylcarbodiimide (DCC) (500.00 mg, 2.42 mmol) for two hours at room 
temperature. N-hydroxysuccinimide (300.00 mg, 2.60 mmol) was dissolved separately 
in 2 ml dry DMSO and was added to the solution above. The mixture was stirred in light 
protected container for 24 hours at room temperature under nitrogen environment. After 
24 hours, the solution was filtered and the filtrate solvent was concentrated by half using 
vacuum distillation at 40 
o
C. The solution was precipitated in the mixture of acetone : 
diethyl ether (30 : 70 v/v ratio) and followed by filtration.The precipitate was washed 
with 100 ml of mixture of acetone : diethyl ether (30 : 70 v/v ratio) and diethyl ether (3 x 
100 ml) and vacuum dried overnight. The product was solid yellow powder (1.00 g, 60% 
). 
1
H NMR (DMSO, 250 Mhz): δH = 11.52  (broad, 1H, COOH), 8.65 (d, J=8.00, 1H,  
CH), 8.16 (d, J=8.00, 1H, NH), 7.67 (t, J= 8.00, 1H, CH), 6.97 (t, J = 8.00, 1H, NH), 
6.66 (t, J= 8.00, 1H, CH), 4.85 (m, 2H, NH2), 4.53 (s, 1H, CH), 2.81 (m, 4H, NHS 
hydrogen), 2.34 (m, 2H, CH2), 2.11 (m, 2H, CH2). 
13C NMR (DMSO, 250 Mhz):δc 
=174.4, 173.2, 154.2, 128.4, 121.7, 52.2, 40.1, 39.3, 30.8, 26.4. MH
+
 (ESI-MS) = 539 
(calculated 538 gmol
-1
), C23H22N8O8, Elemental analysis, C: 51.78%, H: 5.10 %, 
N:19.20%, O: 23.92% (calculated C: 51.30%, H: 4.12%, N: 20.81%, O:23.77%) 
 
 
Synthesis of folate-polyethylene glycol bis amine (Folate-PEG-NH2) 
Polyethylene glycol bis amine (300.00 mg, 0.10 mmol) was dissolved in 5 ml dry DMF. 
Folic acid ester (100.00 mg, 0.18 mmol) was dissolved in 2 ml dry DMF separately and 
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was added to the above solution. Then, diisopropyl ethylamine (100.00 mg, 0.77 mmol) 
was added and the mixture was stirred at room temperature for 24 hours under  nitrogen 
condition. The volume of the solution was reduced using vacuum distillation and was 
precipitated with diethyl ether. The precipitated was washed with diethyl ether for three 
times and dried under vacuum. The product obtained was solid yellow powder. (0.15 g, 
30%). 
1
H NMR (DMSO, 250Mhz): δH = 8.67 (s, 1H), 7.63 (d, 2H), 6.67 (d, 2H), 3.52 
(PEG), 
13C NMR (DMSO, 250 Mhz):δc 175.2, 173.3, 70.2, MALDI –TOF MS : 3151 
 
Synthesis of polyglycidol-folate-polyethylene glycol (PG- Folate-PEG) 
PG-SA (100.00 mg, 0.05 mmol) was dissolved in 3 ml dry DMSO and was activated by 
dicyclohexylcarbodiimide (DCC)(150.00 mg, 0.072 mmol) in dry DMSO (3 ml) in the 
presence of pyridine (5.8 µl, 0.072 mmol). Then folate-PEG-NH2 (300.00 mg, 0.08 
mmol) was dissolved in 3 ml dry DMSO and was added to the above solution. The 
reaction was stirred overnight at room temperature in N2 atmosphere. After the reaction 
complete, the solvent was evaporated and distilled water added to the sample. The 
remaining yellow solution was freezed dried overnight. The product was pale yellow 
solid (150.00 mg, 27% ). 
1
H NMR (DMSO, 250Mhz): δH = 8.70 (s, 1H), 7.55 (s, 1H), 
6.69 (s, 1H), 4.69 (s, 2H), 4.96 – 3.24 (polyglycidol backbone), 2.63 ( s, 4H), 1.65 
(broad, 2H), 1.20 (broad, 3H). 
13C NMR (DMSO, 250 Mhz):δc 175.3, 173.8, 72.1, 69.5, 
62.54, GPC (Mn) 2151 
 
 
7.4 Comparison between PAMAM dendrimer and hyperbranched polymer 
 
Synthesis of G0.5 PAMAM dendrimer holding 4 methyl ester terminal groups 
Methyl acylate (25.1g, 0.29 mol) was added dropwise for 30 minutes to a solution of 
EDA (2.56 g, 43.00 mmol) dissolved in methanol (20 ml) at 0 
o
C in a 500 ml round 
bottom flask. The reaction was stirred overnight at room temperature. Excess methyl 
acrylate was removed in vacuo and placed under high vacuum for a few hours. The 
product was yellow honey oil (13.5g, 48%). 
1
H NMR (MeOD, 250 Mhz): δH = 3.68 (s, 
12H, CH3), 2.76 (t, 8H, NCH2CH2C=O), 2.54 (s, 4H, NCH2CH2N), 2.49 (t, 8H, 
OC=OCH2). 
13
C NMR (MeOD, 250 Mhz): 171.8, 47.1, 32.2,  FTIR λmax: 3283 (amide, 
NH),  2974  (CH-sp2), 1730 (ester carbonyl), 1640 (amide carbonyl), 1534 (amide NH 
bend), 1464 (CH2 bend) cm
-1
. MALDI –TOF MS : 405 
 
Synthesis of G1.0 PAMAM dendrimer holding 4 amine terminal groups 
The ester intermediate PAMAM G0.5 dendrimer (6.70 g, 17.00 mol) was dissolved in 
methanol (50 ml) and added dropwise to EDA (48.90 g, 0.82 mol), in a round bottom 
flask (500 ml) at 0 
o
C. The reaction was kept stirring for 5 days. Purification was done 
using 9:1 (toluene : methanol) azeotropic solution and followed by washing with 
methanol. The mixture was then underwent rotary evaporation and placed under high 
vacuum. The product was a viscous yellow/brown oil (5 g, 8.99%). 
1
H NMR (MeOD, 
250 Mhz): δH = 4.93 (s, 4H, NH), 3.69(s, 8H, NH2), 3.33-3.27 (mm, 16H, H2NCH2 + 
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CH2NH), 2.81-2.41 (m, 20H, C=OCH2CH2 + NCH2CH2N). 
13
C NMR (MeOD, 250 
Mhz): 173.7, 51.0, 49.9, 48.2, 38.1, 33.3, FTIR λmax: 3280 (amide, NH),  2987  (CH), 
1634 (amide carbonyl), 1544 (amide NH bend), 1438 (CH2 bend) cm
-1
. MALDI –TOF 
MS : 517(MH
+
) 
 
Synthesis of G1.5 PAMAM dendrimer holding 8 methyl ester terminal groups 
The diamine intermediate PAMAM G1.0 dendrimer (2.50 g, 4.80 mol), was dissolved in 
methanol (50 ml) and placed into round bottom flask (500 ml). Methyl acrylate (7.30 g, 
85.00 mmol), was added drop wise to the solution for 30 minutes at 0 
o
C. The solution 
was left stirring for 24 hours at room temperature. Excess methyl acrylate was removed 
via rotary evaporator. The solution was then placed under high vacuum for a few days to 
remove traces of reagent yielding 3.20 g, (72 %). 
1
H NMR (MeOD, 250 Mhz): δH = 4.91 
(s, 4H, NH), 3.69 (s, 24H, CH3), 3.39-3.21(m, 24H, NHCH2 + NHCH2CH2CHNCH2), 
2.87-2.35 (mm, 44H, NCH2CH2N + NCH2CH2C=ONH + NHCH2CH2N + 
CH3OC=OCH2). 
13
C NMR (MeOD, 250 Mhz): 173.3, 173.2, 52.4, 50.7, 49.8, 49.1, 37.1, 
32.2, 31.9, FTIR λmax: 3231 (amide, NH),  2952  (CH), 1640 (amide carbonyl), 1592 
(amide NH bend), 1431 (CH2 bend) cm
-1
. MALDI –TOF MS : 1430(MH+) 
 
Synthesis of G2.0 PAMAM dendrimer holding 8 amine terminal groups 
EDA (51.20 g, 0.85 mol), was added dropwise to a stirred solution of the ester 
terminated intermediate produced from previous step (6.60 g, 5.50 mmol) in methanol 
(30 ml) at 0 
o
C. The reaction was stirred for 7 days. The solution was then washed with 
azeotropic mixture of 9:1 toluene: methanol for excess EDA removal. The left over 
solvent was then removed under vacuo. The product was yellow honey/brown viscous 
oil (7.10 g, 90 %). 
1
H NMR (MeOD, 250 Mhz): δH = 4.92 (s, 4H, NH), 3.65(s, 8H, 
NH2), 3.40-3.20 (m, 24H, NHCH2CH2N + NH2CH2CH2NH), 2.89-2.26 (mm, 76H, 
NH2CH2CH2NH + NCH2CH2C=O + NCH2CH2NH + NCH2CH2N). 
13
C NMR (MeOD, 
250 Mhz): 172.3, 50.7, 48.3, 46.1, 40.2, 35.8, 32.0, 31.8, FTIR λmax: 3280. (amide, NH),  
2987  (CH), 1634 (amide carbonyl), 1544 (amide NH bend), 1438 (CH2 bend) cm
-1
. 
MALDI –TOF MS : 517(MH+) 
 
Synthesis of G2.5 PAMAM dendrimer holding 16 methyl ester terminal groups 
The generation 2.0 amine terminated PAMAM dendrimer (1.25 g, 0.87 mmol) was 
dissolved in 30 ml methanol and methyl acrylate (2.80 g, 0.03 mol) was added dropwise 
for at least 30 minutes  in ice bath (0 
o
C) and stirred for two days at room temperature. 
The solvent and methyl acrylate were removed under vacuo and then put in high vacuum 
for a few days. The product was honey yellow viscous oil (1.8 g, 73.5%). 
1
H NMR 
(MeOD, 250 Mhz): δH = 3.68 (s, 48H, CH3), 3.37 (m, 12H, NHCH2CH2N), 2.93-2.33 
(mm, 152H, OC=OCH2CH2N + NCH2CH2NH + NHC=OCH2CH2N + NCH2CH2N).  
13
C 
NMR (MeOD, 250 Mhz): 173.2, 173.3, 52.4, 50.8, 49.1, 48.3, 37.2, 33.1, 32.2, FTIR 
λmax: 3283 (amide, NH),  2974  (CH-sp2), 1730 (ester carbonyl), 1640 (amide carbonyl), 
1534 (amide NH bend), 1464 (CH2 bend) cm
-1
. MALDI –TOF MS : 3242(MH+) 
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Synthesis of PAMAM dendrimer  with 48 hydroxyl  terminal  group         
The PAMAM dendrimer with generation 2.5 (1.00 g, 0.37 mmol) was dissolved in dry 
DMSO (5 ml) and this solution was added to a stirred suspension of tris(hydroxymethyl) 
aminomethane (750.00 mg, 6.05 mmol) and anhydrous potassium carbonate (850 mg, 
6.05 mmol), in dry DMSO ( 15 ml). The solution was stirred for 72 hours at 50 
o
C under 
nitrogen environment. The solution was filtered and the solvent was removed by half 
using vacuum distillation at 40 
o
C.The viscous yellow oil was dissolved in small amount 
of water,  followed by precipitation using acetone. These step was repeated three times 
before the product was dried overnight in vacuum oven. The  final product was pale 
yellow oil. (1.3g, 60%). 
1
H NMR (D2O, 250 Mhz): δH = 3.64 (s, 96H, CH2OH), 2.21 – 
3.26 (164H, broad series of multiplets, remaining CH2). 
13
C NMR (D2O, 250 Mhz): 
175.4, 174.4, 62.0, 60.5, 51.8, 48.8, 38.4, 37.1, 33.1, FTIR λmax: 3303 (broad , OH), 1657 
(amide carbonyl) cm
-1
. MALDI –TOF MS :4130. 
 
Encapsulation of PAMAM dendrimer with 48 hydroxyl terminal group with TCPP 
and ibuprofen 
PAMAM dendrimer with 48 OH hydroxyl terminal group (10.00 mg, 0.002 mmol) was 
dissolved in methanol (10 ml). Access TCPP and ibuprofen was dissolved separately in 
methanol (10 ml). After all polymer dissolved, both drugs were added and physically 
mixed for 5 minutes. All solvent was removed under vacuo and buffer solution was 
added (10 ml). The solution was filtered and UV measurement was conducted. λmax for 
TCPP = 415nm and ibuprofen = 222 nm 
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